Annual Report • Jun 1, 2024
Annual Report
Open in ViewerOpens in native device viewer

NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS
Impact for a sustainable future

You are cordially invited to attend ICL Group Ltd.'s ("ICL") 2024 Annual General Meeting to be held on Wednesday,July17,2024,at10:00a.m.(Israeltime).Thenoticeofthemeeting,aswellasitemsofbusiness and voting instructions,areincludedinthisdocument.
I would like to take this opportunity and provide an update on the recent developments at ICL and the broadercontextinwhichweoperate.
The past few months have presented us with a unique set of challenges, particularly in the fourth quarter, due to the war in Israel. Despite these adversities, I am pleased to report that our efforts to minimize disruption and maintain production levels have been successful. Additionally, the majority of our employees whohadbeencalledupformilitaryreserveservice,havenowresumedtheirfull-timerolesat ICL.
Despite these external factors, we were able to effectively manage those areas within our control, while swiftly reacting to a changing external environment throughout 2023. Our team did an excellent job managing our supply chain amidst war, political tensions and market volatility. We also continued to gain efficienciesanddrivedowncostsacrossthebusiness.
Asaresult,we wereable todeliverasolidperformancein2023,followingarecordyearin2022. For thefull year, we reported sales of \$7.5 billion with adjusted EBITDA of \$1.8 billion(1). We also generated operating cashflow ofmore than\$1.6 billionand\$818millionoffree cashflow,reflectingour continued focusoncashgeneration.
For 2023, we delivered \$0.55 of adjusted earnings per share and distributed an annual dividend of \$0.27 per share, in accordance with ourlong-standing policy to pay out up to 50% of adjusted net income to our shareholders.
Our efficiency and cost savings initiatives, which we put inplace early in2023, delivered ahead of plan.While we made some tough decisions to better position ourselves for the future, we also maintained our focus on expanding our strategic partnerships. As a result, we gained market share across some of our key specialtiesbusinesses. We also expanded into additional new end-markets, with the groundbreaking of new advanced facilitiesandthe launchofnew innovativeproducts, which will havealong-termimpactongrowth.
In conclusion, I would like to express my sincere gratitude for your continued support during these difficult times. Iamconfident that ICLwillnavigate thesechallengesandcontinuetobuildonits success.

Sincerely yours, RavivZoller CEOandPresident
(1) Non-IFRS financials measures and reconciliation to IFRS measures are described in the accompanying proxy statement for the ICL 2024 Annual General MeetingandAppendixAthereto.

The following items of businesswill be covered, as more fully described in the accompanying proxy statement: 1. Re-election of YoavDoppelt, AviadKaufman,AvisarPaz, Sagi Kabla,Reem Aminoach, Lior Reitblatt,Tzipi OzerArmon,Gadi Lesin, Michal Silverberg and Shalom Shlomo to serve as directors, effective
as of the date of the Meeting, until the next annual general meeting of shareholders of the Company or until any of their earlier resignation or removal;
Re-election of Dr. Miriam Haran as an external director (within the meaning oftheIsraeliCompanies Law,1999)forasecond three-yearterm;
Approval of an amendment to the Company's Articles of Association in order to allow forindemnification and insurance of directors and officers underthe Israeli Economic Competition Law, 1988 (the "Israeli Competition Law");
Subject to the approval of Proposal 3, approval of an amendment to the exemption, insurance and indemnification undertaking letter issued by the Company to each of its directors and officers to allow for indemnification and insurance in connection withproceedingsunderthe IsraeliCompetitionLaw;
Reappointment of Somekh Chaikin, a Member Firm of KPMG International, as the Company's independent auditor untilthe next annual general meeting of shareholders ofthe Company; and 6. Present and discuss our audited financial statements forthe year ended December 31, 2023.
IfyouareaholderofrecordofourOrdinary Sharesasofthe close ofbusinesson June 10, 2024(the "RecordDate"),youare entitled to receive notice of, and to vote in person or by proxy at,the Meeting or any adjournment or postponementthereof. This also applies if you heldOrdinary Shares through a bank,broker,or othernominee (i.e., in "street name")thatis one of our shareholders ofrecord atthe close of business on the Record Date, or which appeared in the participantlisting of a securities depository (such as the DepositoryTrustCompany)onthatdate.IfyouheldourOrdinary Shares throughthe TelAviv Stock Exchange ("TASE")on the Record Date, you are also entitled to notice ofthe Meeting and to vote atthe Meeting or any adjournment or postponement thereof
The accompanying proxy statement includes important information about the Meeting and the voting process. Pleasereaditcarefullyandremembertocastyourvote.
Record holders: Shareholders ofrecord can vote either by mailing in a proxy orin person by attending the Meeting.If you are a shareholder ofrecord and will not attend the Meeting in person, you are requested to complete, date, and signtheenclosedformofproxyandreturnitpromptly,nolaterthan48hoursbeforetheMeeting,inthepreaddressed envelope provided. No postage is required if mailed in the United States. If you are a shareholder
ofrecord and attend the Meeting, you may revoke your proxy (if previously submitted) and vote in person.
Beneficialholders: If your shares are held in a stock brokerage accountor by a bank orothernominee, you are considered the beneficial owner of shares held in "street name." Your broker, bank, or nominee will provide you with instructions that you must follow to have your shares voted. If you are a beneficial holder and wish to vote in person atthe Meeting, you mustfirst obtain a "legal proxy"from your
broker, bank, or nominee that holds your shares, giving you the right to vote the shares at the Meeting.
Shares Traded on the TASE: If you hold your shares through a member ofthe TASE, you may vote your shares in person or by delivering or mailing (via registered mail) your completed Hebrew written ballot (in the form filed by the Company via MAGNA, the online platform
of the Israel Securities Authority ("ISA")) to the offices of the Company not less than four hours prior to the time scheduled for the Meeting. Shareholders who hold shares through members of the TASE (whether attending the Meeting in person or voting through a voting ballot) must deliver to the Company an ownership certificate confirming their ownership of our ordinary shares as ofthe Record Date from the
applicableTASEmember,asrequiredbytheIsraeliCompaniesRegulations(Proof of Ownership of Shares for Voting at General Meeting) of 2000, as amended. Alternatively, shares held via a TASE member may be voted electronically via the ISA's electronic voting system up to six hours before the time fixed for
the Meeting. Shareholders should receive instructions about electronic voting from the TASE memberthrough which they hold their shares.
The 2024 Annual GeneralMeeting of Shareholders (the "Meeting") of ICL Group Ltd.(the "Company") will be held:
At the offices of the Company, Millennium Tower,23AranhaStreet, 22ndFloor,TelAviv,Israel and virtuallyvia Microsoft Teamsatthis link
When: Wednesday,July17,2024
10:00 a.m. (Israeltime)
Shareholders may review the full version of the proposed resolutions in the Proxy Statement as well as the accompanying proxy card, via the website of the U.S. Securities and Exchange Commission at www.sec.gov or via the ISA's electronic filing system at http://www.magna.isa.gov.il or the website of the TASE at http://www.maya.tase.co.il,
and also at our offices
during regular business hours, upon prior coordination (Millennium Tower, 23 Aranha Street,
22nd Floor, Tel Aviv, Israel; Tel: +972-3-6844400), until the Meeting. Our company's representative is Aya Landman, VP, Chief Compliance Officer & Corporate Secretary (Millennium Tower, 23 Aranha Street, 22nd Floor, Tel Aviv, Israel; Tel: +972-3- 6844435).
By Order of the Board of Directors, Aya Landman, Adv. VP, Chief Compliance Officer & Corporate Secretary May 31, 2024

This Proxy Statementis furnished to the holders of Ordinary Shares, par value NIS 1.00 per share (the "Ordinary Shares"), of ICL GroupLtd.(the "Company,""ICL,""we,""us" or"our")inconnectionwiththesolicitationby theBoardofDirectorsofthe Company (the "Board of Directors" or "Board") of proxies for use at the 2024 Annual General Meeting of Shareholders (the "Meeting"),or at any postponement or adjournment thereof, pursuant to the accompanying Notice of 2024 Annual General Meeting of Shareholders.TheMeetingwillbeheldonJuly17,2024,at10:00a.m.(Israeltime),attheofficesoftheCompany,MillenniumTower,23 Aranha Street, 22nd Floor, Tel Aviv, Israel and via Microsoft Teams (meeting URL: https://teams.microsoft.com/l/meetupjoin/19%3ameeting_NzdlMWZjYjEtZTU4OC00Y2E1LThmNDQtMTYxY2ViOGUwMDVl%40thread.v2/0?context=%7b%22Tid%22%3a% 22802762d2-02c4-4677-98ba-54060a234204%22%2c%22Oid%22%3a%22c24a4bb8-71f6-47d6-8612-141e27ea57a2%22%7d). If you intendtoparticipateinthemeetingviaMicrosoftTeams,werecommendlogginginatleastfifteenminutesbeforethe MeetingtoensurethatyouareloggedinwhentheMeetingstarts.
This This proxy statement may contain forward-looking statements within the meaning of the United States Private SecuritiesLitigation Reform Act of 1995 and other applicable securities laws. Whenever words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "predict," "strive," "target," "up to," "expansion," or similar expressions are used, the Company is making forward-looking statements. Such forward-looking statements may include, but are not limited to, those that discuss strategies, goals, targets, objectives, financial outlooks, corporate initiatives, our long-term business, financial targets and outlook, current expectations, existing or new products, existing or new markets, operating efficiencies, or other non-historicalmatters. Because such statements deal with future events and are based on our current expectations, they could be impacted or be subject to various risks and uncertainties, including those discussed in the "Risk Factors" section and elsewhere in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 14, 2024 (the "2023 Annual Report"),andinsubsequentfilingswiththeU.S. SecuritiesandExchange Commission("SEC")andtheIsrael SecuritiesAuthority ("ISA").Our strategies, business and financialtargets, goals and objectives are subjectto change fromtime to time. Therefore, actualresults, performance or achievements ofthe Company could differ materially fromthose described in or implied by such forward-looking statements due to various factors, including, but not limited to risk factors discussed under Item 3 – Key Information – D. Risk Factors in the 2023 Annual Report. Forward looking statements speak only as of the date they are made and, except as otherwise required by law, the Company does not undertake any obligation to update them in light of new informationorfuturedevelopmentsortoreleasepubliclyanyrevisionstothesestatements,targetsorgoalsin ordertoreflect later events or circumstances or to reflect the occurrence of unanticipated events. Readers, listeners and viewers are cautionedto consider these risks and uncertainties and to not place undue reliance on such information. Forwardlooking statements should not be read as a guarantee of future performance or results and are subject to risks and uncertainties, and the actual resultsmaydiffermateriallyfromthoseexpressedorimpliedintheforward-lookingstatements.
Included in this proxy statement are financial measures that are not prepared in accordance with International Financial Reporting Standards ("IFRS"), such as EBITDA, adjusted EBITDA, adjusted net income attributable to the Company's shareholders, diluted adjusted earnings per share and net debt to adjusted EBITDA, which were designed to complement the financial information presented in accordance with IFRS. Our management uses these non-IFRS measures to evaluate the Company's business strategies and performance. We believe that these non IFRS measures provide useful information to investors because they improve the comparability of our financial results between periods and provide for greater transparencyof key measures used to evaluate our performance. These non-IFRS financial measures should be considered only as supplemental to, and not superior to, financial measures provided in accordance with IFRS. Other companies may calculate similarly titled non-IFRS financial measures differently than the Company. Please refer to page 40 and Appendix A of this proxy statement for additional information about such non-IFRS financial measures and reconciliation of the non-IFRS financial measures included in this proxy statement to the most directly comparable financial measures prepared inaccordancewith IFRS.
This summary highlights certain information that you should consider before voting ontheproposalstobepresentedattheMeeting.Thissummarydoesnotcontainallof theinformationthatyoushouldconsider,andyoushouldreadtheentireProxy Statementandour2023AnnualReportcarefullybeforevoting.
DATE: July 17, 2024
TIME: 10:00 a.m. Israel Time VIRTUAL MEETING :atthislink RECORD DATE :June10,2024
CORPORATE WEBSITE: www.icl-group.com INVESTOR WEBSITE: https://investors.icl-group.com 2023 ANNUAL REPORT: https://s27.q4cdn.com/112109382/files/doc_ financials/2023/ar/20F-Final-2023_Accessibility.pdf
| PROPOSAL | BOARD RECOMMENDATION |
PAGE | |
|---|---|---|---|
| .1 | Re-election of ten directors to serve until the next annual general meeting of shareholders of the Company or until any of their earlier resignation or removal |
FOReachdirector | 20 |
| .2 | Re-election of Dr. Miriam Haran to serve as an external director, within the meaning of the Israeli Companies Law, 1999, for a second three-year term |
FOR | 20 |
| .3 | Approval of an amendment to the Company's Articles of Association in order to allow for indemnification and insurance of our directors and officers under the Israeli Economic Competition Law, 1988 |
FOR | 21 |
| .4 | Subject to the approval of Proposal 3, approval of an amendment to the exemption, insurance and indemnification undertaking letter issued by the Company to each of its directors and officers to allow for indemnification and insurance in connection with proceedings under the Israeli Competition Law, 1988 |
FOR | 21 |
| .5 | Reappointment of Somekh Chaikin, a Member Firm of KPMG International, as the Company's independent auditor until the next annual general meeting of shareholders of the Company |
FOR | 22 |
In2024, ICLwillremainfocusedonexecuting ourfive-yearplan, leveraging new opportunities in our specialties businesses, with consistent cost discipline, and resolve to deliver innovativeandsustainablesolutionstoour customers around the world. This is in line with our strategy to be leaders in specialty/downstreambusinessesbasedonourunique mineralresources, customer relationships, and technological ingenuity,asweoptimizethecommodityvalueofour resources.

Expanding long-term specialties focus & increasing capacity to enablegrowthinspecialties

CommittingtochallengingESGKPI's, aswellasdriving ICL'sdiversityandinclusion

InvestinginR&Dtoinnovateandexpand ourspecialtyproductportfolio

Maintaining focus on long-term customer relationships and a sustainable supply chain

Continued focus on cash generation, and generating returns to our shareholders while capitalizing on business expansion opportunities, based on a strong balance sheet
Throughoutthe fiscal year of 2023, with a particular emphasis on the fourth quarter, we demonstrated effective management of our internal operations while simultaneously adapting to an evolving external environment. Our team exhibited resilience in managingour supply chain amidst global challenges such as war, political instability, and market fluctuations. Furthermore, we persistently pursued efficiency gains and cost reductions across all business sectors. Consequently, we were able to maintain robust performancein2023,followingarecord-settingyearin2022.
Forthe entire year, we reported sales amounting to \$7.5 billion and adjusted EBITDA of
\$1.8 billion. We maintained a consistent focus on cash flow throughout 2023, generating an operating cash flow exceeding \$1.6 billion and free cash flow of \$818 million. Our prioritization of cash flowand agility became increasingly crucial post-October 7, 2023, as wenavigatedthroughproductionandlogisticalchallengeswhileexpeditingadditional efficiencymeasures.
In 2023, we delivered \$0.55 of adjusted earnings per share and distributed an annual dividend of \$0.27 per share, as part of our long-standing policy to distribute dividends to our shareholders. The efficiency and cost-saving initiatives that we implemented early in 2023 were executed ahead of schedule. While we made some challenging decisions to better position ourselves for the future, we also sustained our focus on expanding our strategic partnerships. As a result, we increased our market share across several of our keyspecialtybusinesses.
We concluded 2023 with fourth-quarter sales of \$1.7 billion and adjusted EBITDA of \$357 million. Although sales experienced a year-over-year decline as anticipated, they exhibitedanincreasecomparedto2021.
| US\$M Per share ex. |
FY'22 | FY'23 |
|---|---|---|
| Sales | \$10,015 | \$7,536 |
| Net income,attributabletotheCompany'sshareholders | \$2,159 | \$647 |
| Adjustednet income,attributabletotheCompany'sshareholders | \$2,350 | \$715 |
| Dilutedearningspershare | \$1.67 | \$0.50 |
| Adjusteddilutedearningspershare | \$1.82 | \$0.55 |
| AdjustedEBITDA | \$4,007 | \$1,754 |
| 2023 NON-FINANCIAL PERFORMANCE |
||
| US\$M Per share ex. |
FY'22 | FY'23 |
| GHGEmissions | 2,407 | 2,288 |
| Incident Rate | 0.62 | 0.70 |
| Percentofwomeninseniorleadership | 23% | 25% |
| Communityinvestment | \$14.5 | \$7.1 |
Wearededicatedtoupholdingthe highest standards of corporate governance, recognizing its fundamentalroleinguiding our operations and shaping our ethical framework. Guided by our mission of – 'doing the right thing, in the right way, everyday', our commitment extends beyond compliance; it reflects our dedication to fostering a culturethatprioritizes integrity, ethical conduct, transparency and accountability in all aspects of our business practices. By embedding robust governance systems and principles,weaimtonotonlymeet, butexceed,theexpectationsofour stakeholders. This commitment underscoresourmissiontoImpact foraSustainableFuture,driving us to integrate sustainability intoeveryaspectofourdecisionmakingprocesses,whileensuring transparency, responsibility, and valuecreation.
OurBoardofDirectorsoverseesthe management of ICL's business. We have robust governance systems in place, encompassing policies and processes that delineate the roles and responsibilities of both our BoardandtheSeniorManagement team. Presented in this page key highlights of these practices and policies.
Assuming all of the director nominees are elected at the Meeting, our board of directorswill include 33% female representation (4 out of12). Assuming all of the director nominees are elected at the Meeting, our board of directors will include 33% female representation (4 out of 12). ICL is committed to increasing the percentage of female representation in our board to 45% by the end of 2028.
As an Israeli publicly traded company, we are required by the IsraeliCompaniesLaw,1999(the "Israeli Companies Law"),tohaveat leasttwo external directors serving on our board of directors. Such external directors must be completely independent, unaffiliated with the Companyor the controlling shareholder. External directors are elected, by law,foraperiodofthree consecutive years, to preserve their independence.Allthemembers of our Audit & Accounting and HR & Compensation Committees are independent under the Israeli CompaniesLawandtheNYSErules.
Assuming all of the director nominees (including the externaldirector nominee) areelected at the Meeting, 8 out of 12 of our directors (67%) will be independent.
None of our director nominees sit togetheron the board of directors of any otherpublic company.
97%Attendanceatall 2023Boardof Directors meetings (excluding Mr. Ovadia Eli who concluded his tenure as an ICL director on May 10, 2023).
At each annual meeting of shareholders of ICL, each director,who is not an 'external director' under Israeli law, is electedtoholdoffice for a one-year term expiringat the next annual meeting of shareholdersof ICL.
TheBoardincludes 6 new directors who have joined since 2020.
Annual self-evaluationsare conducted by our Boardof Directors.
The Company has a tailored and robust onboarding program for new directors, aimed to familiarizenewdirectorswithkey topics. The program is formalized and tailored with consideration to the unique backgrounds, experiences and expected committee responsibilities of eachnewdirector.
Weare committed toprotecting our employees, the environment, and the communities in which we operate. Our actions are governed by our Climate, Sustainability & Community Relations committee (the "CSC Committee"). Our CSC Committee, chaired by Dr. Miriam Haran, a seasoned environmental expert, oversees ICL's: (1) climate, sustainability, safety, environment, and water management related risks and opportunities, targets, policies and programs; (2) community outreach programs, public relations and advocacy, and (3) diversity and inclusion aspects intheCompany.

table below shows summary information about each nominee for election as a director and an external director at the Meeting, as well as our additional external director.
| NOMINEEFORELECTION AGE ASDIRECTOR |
DIRECTOR SINCE | INDEPENDENT | COMMITTEEMEMBERSHIP | |||||
|---|---|---|---|---|---|---|---|---|
| UNDERTHE COMPANIESLAW |
UNDERTHE NYSERULES |
A&A | COMP | CSC | FIN | |||
| YoavDoppelt (chairmanoftheBoard) |
55 | December 2018 and as CoB since July 2019 |
(*) | |||||
| AviadKaufman | 53 | March 2014 | (*) | ° | ||||
| Avisar Paz | 67 | April 2001 | (**) | ° | ||||
| LiorReitblatt | 66 | November 2017 | v v |
° | ° | |||
| Reem Aminoach 66 March 2017 |
(***) | v | ° | |||||
| SagiKabla 47 February 2016 |
(*) | ° | • | |||||
| TzipiOzerArmon | 58 January2020 |
v | v | |||||
| GadiLesin | 57 | March 2021 | v | v | ° | ° | ||
| Michal Silverberg 47 July2022 |
(***) | v | ||||||
| Shalom Shlomo 46 |
January2024 v |
v | ||||||
| Our External Director standing for reelection at the AGM | ||||||||
| Dr.Miriam Haran 74 |
v | v | ||||||
| Our additional External Director (not standing for reelection at the AGM) | ||||||||
| DafnaGruber 58 January2022 |
v | v |
(*) Messrs.YoavDoppelt,AviadKaufmanandSagiKablaarenot consideredindependentdirectorsunderthe Companies LawandNYSE rulesby virtueof the positions they hold, or previously held,with our controlling shareholder orin the Company.
(**) TheBoardexpectsMr.PaztobegintoqualifyasanindependentdirectorunderNYSEcorporategovernancerulesinJuly2024.
The Board will assess Mr.Paz's independence in July 2024.
(***) Mr.ReemAminoachandMs.Michal Silverbergmeetallqualificationsunderthe Companies LawforIndependentDirectorbutwerenotformally classifiedasones.
A&A - Audit & Accounting Committee | CSC - Climate, Sustainability & Community Relations Committee |• Committee Chair
Comp - HR&CompensationCommittee | Fin–Financing Committee | °CommitteeMember

The Company's Board of Directors has adopted guidelines for institutionalizing and improving the structure and composition of the Board of Directors, reflecting, among other things, the Company's ambition to maintain a diverse composition of its board of directors, which represents diverse backgrounds, expanding skillsets and experience, and encompasses a wide range of special expertise, such as high-level managerial experience in a complex organization; strong global experience; skills and experience in dealing with complex issues; experience with strategy setting; experience in managing global businesses, workingwith emerging markets and business development experience in high-volume businesses; experience in corporate governance, sustainabilityandenvironmentalexpertise,riskmanagementandregulation,andgenderdiversity.
The guidelines further include guiding principles for the appointment of external directors in the Company. In addition, the Company strives to have a board of directors comprised of directors with the following expertise: industry expertise; corporate governance expertise; environmental, biodiversity and climate expertise; logistics and operational expertise and safety expertise.
Accordingly,the Company strives to integrate within its board, directors with expertise in such areas, whether with new appointmentsoruponreplacementofadirector'svacantposition.
Further information regarding the composition of our Board of Directors is detailed hereunder in our Board competence profilematrix:
| YoavDoppelt Executive Chairman oftheBoard |
Kaufman man Aviad Kauf |
Avisar Paz Paz |
Reitblatt Reitblatt Lior |
Aminoach Aminoach m Ree |
Kabla Kabla Sagi |
Armon Tzipi Ozer mon Ozer Ar |
Lesin Lesin Gadi |
m Dr. Miria Haran Haran |
Gruber Dafna |
Silverberg Silverberg Michal |
Shlomo m mo Shalo Shlo |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leadership experience in managing companies, associations and networks |
||||||||||||
| Industry/Commercial expert | ||||||||||||
| other economic sectors | ||||||||||||
| Finance,financialreporting, law and compliance |
||||||||||||
| Sustainabilitytopics | ||||||||||||
| Accounting and auditing, sustainability reportingandriskmanagement |
||||||||||||
| Innovation,research&development and technology |
||||||||||||
| Digitalization,IT,businessmodels andstart-ups |
||||||||||||
| Human resources, society, communicationsand themedia |
||||||||||||

The Board of Directors considers the qualifications of each director candidate and the overall composition of the Board. We are committed to diversity and a balance of tenure that brings experience as well as new perspectives to Board deliberations

TENUREOF OUR 7 INDEPENDENT DIRECTOR NOMINEES

Our executive compensation program's total direct compensation includes a traditional base salary, with additional guaranteedsalary items such as: social benefits, social and related provisions, Company car and reimbursement of telephone expenses, short-term incentives tied to financial, operational, and strategic performance and long-term incentives linked to share price performance.
The following charts illustrate the mix of the fixed compensation (base salary and guaranteed compensation items), as well as the short- and long-term incentive compensation that comprised the 2023 total direct compensation for Mr. Zoller and theaverage total direct compensation for the 5-top earning executive officers as a group, represented by each compensation component.

As an Israeli public company, we are required to adopt a compensation policy for Office Holders, as such term is defined in the Israeli Companies Law, once every three years. Our current Compensation Policy, which reflects our executive compensation philosophy and creates a coherent system of rules and principles for compensation and incentives for these executives, was approved in 2022 by our HR & Compensation Committee, Board of Directors and our shareholders by a special majority (of noncontrolling and disinterested shareholders), in that order.

A majority of the targeted total direct compensation is at-risk and tied to performance We maintain an appropriate balance between short-term and long-term compensation to provide appropriate balance between short- and long-term decision making and discourage excessive risk taking
Our executive compensation is governed by a strict compensation policy, approved by our shareholders by a special majority once every three years
Our HR & Compensation Committee is an independent committee, comprised of independent directors only
In 2023, we adopted a Compensation Recoupment Policy("claw back"). This policy requires us to reasonably promptly recover incentive-based compensation received by executive officers in the event of certain restatements of the Company's financial statements. In addition, our Compensation Policy includes a claw back provision that is applicable to variable compensation of Office Holders (as such term is defined in the Israeli Companies Law).
We do not award uncapped incentives that could contribute to excessive risk taking We do not reprice options under our equity plan We do not enter into executive
employment agreements without an ability to terminate the agreement within a framed time cap



Appendix A – Reconciliation of Non-IFRS Measures Full Year 2023 Annex A – Annotated Articles of Association 40
Annex B – Annotated Exemption, Insurance and Indemnification Undertaking Letter


You are entitled to notice of, and to vote in person or by proxy at,the Meeting or any adjournment or postponementthereof, if youareaholderofrecordofourOrdinarySharesasofthecloseofbusinessonJune10,2024("RecordDate").Youarealso entitled to notice of the Meeting and to vote at the Meeting or any adjournment or postponement thereof if you held Ordinary Shares through a bank, broker or other nominee thatis one of our shareholders ofrecord atthe close of business on the Record Date, or which appeared in the participant listing of a securities depository (such as the Depository Trust Company) on that date,andifyouheldyoursharesthroughtheTASEonthatdate.Seebelow"HowYouCanVote."
There were 1,314,471,225 Ordinary Shares outstanding on May 28, 2024.
Youwill beaskedtovote onthe followingitems of business::
Re-electionofYoavDoppelt,AviadKaufman,AvisarPaz,SagiKabla,ReemAminoach,LiorReitblatt,TzipiOzerArmon,Gadi Lesin, Michal Silverberg and Shalom Shlomo to serve as directors, effective as ofthe date ofthe Meeting, untilthe next annualgeneral meetingofshareholdersoftheCompanyoruntilanyoftheirearlierresignationorremoval;
Re-election ofDr. MiriamHaran to serve as an external director ofthe Company, within the meaning ofthe Israeli Companies Law,1999(the"IsraeliCompaniesLaw"),forasecondthree-yearterm;
Approval of an amendment to the Company's Articles of Association, to allow for indemnification and insurance of directors andofficersundertheIsraeliEconomicCompetitionLaw,1988(the"IsraeliCompetitionLaw");
Subject to the approval of Proposal 3, approval of an amendment to the exemption, insurance and indemnification undertaking letter issued by the Company to each of its directors and officers to allow for indemnification and insurance in connectionwithproceedingsundertheIsraeliCompetitionLaw;and
Reappointment of Somekh Chaikin, a Member Firm of KPMG International, as the Company's independent auditor untilthe nextannualgeneralmeetingofshareholdersoftheCompany.
At the Meeting, following the matters to be voted on as detailed above, we will also present and discuss our audited financial statements forthe year endedDecember 31, 2023, as previouslymade available to our shareholders as part of our 2023Annual Report, which may be accessed via the SEC's website at www.sec.gov and the ISA's website at http://www.magna.isa.gov.il (referencenumber2024-02-022207),aswellasviathe"Investor" sectionofourCompany'swebsite,www.icl-group.com.
The Company currently is not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, or any adjournment or postponement thereof, the persons designated as proxies may vote in accordance withtheirjudgmentonsuchmatters.
Two or more shareholders holding in the aggregate more than 50% ofthe outstanding voting powerin the Company, presentin person or by proxy, written ballot or via the ISA's electronic voting system, and entitled to vote, will constitute a quorum at the Meeting. If within half an hour from the time scheduled forthe Meeting a quorum is not present,the Meeting shall be adjourned to July 24, 2024, at the same time and place. If a quorum is not present within half an hour from the time scheduled for the adjourned meeting, then two shareholders with voting rights, who hold in the aggregate at least one-third of the Company's issued share capital, who are present, in person or by proxy, written ballot or via the ISA's electronic voting system, shall constitute a quorum. This notice will serve as notice of such reconvened meeting if no quorum is present at the original date andtimeandnofurthernoticeofthereconvenedmeetingwillbegiventoshareholders.
In the case of joint holders of Ordinary Shares, pursuant to Article 75 of the Articles of Association of the Company, the vote ofthe most senior of such joint holderswho tenders a vote, in person or by proxy,will be accepted to the exclusion ofthe vote(s) ofthe otherjoint holder(s). Forthis purpose, seniority will be determined by the orderin which the names stand in the Company's ShareholdersRegister.
Abstentions and broker non-votes will be counted towards the quorum. Broker non-votes occur when brokers that hold their customers' shares in street name sign and submit proxies for such shares, and vote such shares on some matters but not on others. This occurs when brokers have notreceived any instructions from their customers, in which case the brokers, as the holders of record, are permitted to vote on "routine" matters, but not on non-routine matters. Unsigned or unreturned proxies, includingthosenotreturnedbybanks,brokers,orotherrecordholders,willnotbe countedforquorumpurposes.

Each Ordinary Share is entitled to one vote upon each ofthe proposals to be presented atthe Meeting.
The affirmative vote of the holders of a majority of the voting power in the Company represented at the Meeting, in person or by proxy, written ballot or via the ISA's electronic voting system, and voting on the matter, is required forthe approval of each of theproposals.
In addition,the approval ofthe re-election ofDr.Haran as an external director underItem2 is also subjectto the fulfillment of one of the following additional voting requirements: (i) at least a majority of the shares of non-controlling shareholders and shareholderswhodonothaveapersonalinterestintheresolution(otherthanapersonalinterestthatisnottheresultofthe shareholder's relationship with a controlling shareholder) voted in favor of the election of the external director (abstentions and broker non-votes are disregarded); or(ii)the total number of shares voted againstthe election ofthe external director by shareholders referredtoinclause(i)doesnotexceedtwo-percent(2%)oftheoutstandingvotingpowerintheCompany.
In addition, the approval of the amendment of the exemption, insurance and indemnification undertaking letter issued by the Company to directors and officers under Item 4 shall also be subject to the fulfillment of one of the following additional voting requirements: (i) atleast a majority ofthe shares of non-controlling shareholders and shareholders who do not have a personal interest in the proposal voted in favor of the proposal (abstentions and broker non-votes are disregarded); or (ii) the total number of shares voted against the proposal by shareholders referred to in clause (i) does not exceed two-percent (2%) of the outstandingvotingpowerintheCompany.
TheIsraeliCompaniesLawrequiresthateachshareholdervotingonItem2(there-electionofDr.Haranasan external director)andItem4(theamendmentof theexemption,insuranceandindemnificationundertaking letter fordirectorsandofficers)informtheCompany,priortovotingonsuchproposalsattheMeeting,ifthe shareholderhasapersonal interestintheproposals(inthecaseofItem2,excludingapersonalinterestthatisnot relatedtotheshareholder's relationship with a controlling shareholder); otherwise, a shareholder's vote will not be counted for the purposes ofItems2and4. InaccordancewithregulationspromulgatedundertheIsraeli CompaniesLaw,ashareholdervotingvia proxycardorwrittenballotonItems2and4willbedeemedtohave confirmedthathe/she/itdoesnothaveapersonalinterest in such proposals, unless the shareholder has delivered a written notice to the Company notifying of the existence of a personal interest no later than 10:00 a.m. (Israel time) on July 16, 2024. Any such written notice must besenttotheCompanyviaregisteredmailatthe Company'sofficesatMillenniumTower,23AranhaStreet,22nd Floor,TelAviv, Israel; Attention: Aya Landman, VP, Chief Compliance Officer & Corporate Secretary. All other shareholders voting onItems2and4arerequiredto indicateviatheISA'selectronicvotingsystem,or,ifvotinginpersonattheMeeting, inform us prior to voting on the matter at the Meeting, whether or not the shareholder has a personal interest in Items2and4(inthecase ofItem2,excludingapersonalinterestthatisnotrelatedtoarelationshipwithacontrolling shareholder); otherwise,anysuchshareholder'svotewillnotbecountedforthepurposesofsuchproposals.
Underthe Israeli Companies Law, a "personal interest" of a shareholderin an act ortransaction of a company (i) includes a personal interest of(a) any ofthe shareholder's relatives (i.e., spouse, sibling, parent, grandparent or descendant ofthe shareholder, any descendant, sibling or parent of a spouse ofthe shareholder and the spouse of any ofthe foregoing); and (b)a company with respectto which the shareholder or any ofthe shareholder's relatives (as defined above) owns atleast 5% ofthe outstanding shares or voting rights, serves as a director or chief executive officer or has the right to appoint one or more directors orthe chief executive officer; and (ii) excludes a personal interest arising solely fromthe ownership of shares. Under the Israeli Companies Law, in the case of a person voting by proxy,"personal interest"includes the personal interest of eitherthe proxyholderortheshareholdergrantingtheproxy,whetherornottheproxyholderhasdiscretionhowtovote.
Intabulatingthevotingresultsforanyparticularproposal,sharesthatconstitutebrokernon-votesandabstentionsarenot considered votes cast on that proposal. Unsigned or unreturned proxies, including those not returned by banks, brokers, or otherrecord holders, will not be counted for voting purposes. Therefore, itis importantfor a shareholderthat holds Ordinary Sharesthroughabankorbrokertoinstructitsbankorbrokerhowtovoteitssharesiftheshareholderwantsitssharesto counttowardsthevotetallyforagivenproposal.

How you vote depends on whether you are shareholder ofrecord, shareholderin "street name" or shareholder who holds shares that are traded on the TASE. You are a shareholder of record if the share certificate or book-entry position is registered in your name at our transfer agent. You are considered the beneficial owner of shares held in "street name" if your shares are held in a stock brokerage account or by a bank or other nominee. You are considered a shareholder who holds shares that are traded in TASEifyoursharesareheldthroughamemberoftheTASE.
You may attend and vote in person at the Meeting or may submit your vote by completing, signing and submitting (in the enclosed, postage-paid envelope)the enclosed proxy card. Unless otherwise indicated specifically on the form of proxy, Ordinary Shares represented by any proxy in the enclosed form will be voted in favor of all the matters to be presented at the Meeting, as recommended by the Board ofDirectors. To be valid, a proxy must be properly executed and received by ourtransfer agent or attheofficesoftheCompanynoless than48hourspriortothetime scheduledfortheMeeting(i.e.,10:00a.m.(Israeltime)on Monday,July15,2024),unlessashorterperiodisdeterminedbythechairmanoftheMeeting.
Your broker, bank or nominee will provide you with instructions that you must follow in order to have your shares voted. If you are a beneficial holder and wish to vote in person atthe Meeting, you mustfirst obtain a "legal proxy"from your broker, bank or nomineethatholdsyoursharesgivingyoutherighttovotethesharesattheMeeting.
You may vote your shares in person or by delivering or mailing (via registered mail) your completedHebrew written ballot(in the formfiled by the Company via MAGNA,the online platformofthe ISA),to the offices ofthe Company no less than four hours priorto the time scheduled for the Meeting, at the address set forth above, attention: Aya Landman, VP, Chief Compliance Officer & Corporate Secretary. Shareholders who hold shares through members of the TASE (whether attending the Meeting in person or voting through a voting ballot) must deliver to the Company an ownership certificate confirming their ownership of our ordinary shares as of the Record Date from the applicable TASE member, as required by the Israeli Companies Regulations (Proof of Ownershipof Shares forVotingatGeneral Meeting) of 2000, asamended. Alternatively, sharesheldviaaTASEmembermay be voted electronically via the ISA's electronic voting system, up to six hours before the time fixed forthe Meeting. Shareholders should receive instructions about electronic voting from the TASE member through which they hold their shares. If you are a beneficial owner of shares held through a TASE member and you wish to vote in person at the Meeting, you must deliver to us anOwnershipCertificate,asoftheRecordDate,issuedbythatmemberoftheTASE.
Shareholders of record may revoke the authority granted by their execution of proxies by delivering to the Company a written notice ofrevocation or duly executed proxy bearing a later date, provided such revocation notice orlater-dated proxy is receivedby the Company at least 48 hours before the Meeting, unless a shorter period is determined by the chairman of the Meeting, orby attending the Meeting and voting in person. Attendance at the Meeting will not cause your previously granted proxy to be revokedunlessyouspecificallysorequest.
If your shares are held in "street name," you may change your vote by submitting newvoting instructions to your broker, bank, trustee or nominee or, if you have obtained a legal proxy from your broker, bank,trustee or nominee giving you the rightto vote yourshares,byattendingtheMeetingandvotinginperson.
If you are a beneficial owner of shares registered in the name of a member of the TASE and wish to change your voting instructions, you may change your vote (i) by attending the Meeting and voting in person, by presenting a valid ownership certificate (as of the Record Date); (ii) by delivering a later-dated duly executed Hebrew written ballot, together with a valid ownership certificate (as of the Record Date), to the Company's offices no later than four hours prior to the designated time of the Meeting, or(iii) by following the relevantinstructions for changing your vote via the ISA electronic voting system by no later thansixhoursbeforethetimesetfortheMeeting

Proxies for use at the Meeting are being solicited by the Board of Directors of the Company. Proxies are being mailed to shareholdersonoraboutJune12, 2024,andwillbe solicitedmainlybymail. TheCompanywillbearthe costforthesolicitationof the proxies, including postage, printing and handling, and will reimburse the reasonable expenses of brokerage firms and othersfor forwarding materialto beneficial owners ofOrdinary Shares. In addition, certain officers, directors, employees and agent ofthe Company, none of whom willreceive additional compensation therefor, may solicit proxies by telephone, e-mail or otherpersonal contact.
Financial and other information about the Company is available under ICL's profile on the SEC website at www.sec.gov and the ISA's websiteathttp://www.magna.isa.gov.il,as wellas viathe"Investor" sectionofour Company's website, www.icl-group.com.
In addition, any shareholder who would like to receive a copy of our 2023Annual Reportmay do so free of charge by contacting ourregisteredheadofficeatthefollowingaddress:
MillenniumTower, 23AranhaStreet, 22nd Floor, Attention: Aya Landman, VP, Chief Compliance Officer & Corporate SecretaryTel:+972-3-6844435 Email: [email protected]
Any documents referred to in this proxy statement, and any information or documents available on the SEC, ISA, TASE or any other website including our own, are notincorporated by reference into this proxy statement unless otherwise specified.
The information contained in this proxy statementis given as of May 29, 2024, unless otherwise specified.
The following table presents as of May 28, 2024 (unless otherwise noted below)the beneficial ownership of our Ordinary Shares, as determined in accordancewithrules ofthe SEC, by each personwho is knownby us to be the beneficial owner of 5% or more of our outstanding Ordinary Shares. The data presented is based on information provided to us by the holders or disclosed in public regulatory filings. The number of ordinary shares beneficially owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared votingpowerorinvestmentpoweraswellasanysharesthattheindividualhastherighttoacquirewithin60daysthroughthe exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws,thepersonsnamedinthetablehavesolevotingandinvestmentpowerwithrespecttoallcommonsharesheldbythat person.
| SHAREHOLDER | ORDINARY SHARES NUMBER |
BENEFICIALLYOWNED(1) PERCENTAGE |
|---|---|---|
| Israel Corporation Ltd.(2) | 567,012,091 | 43.98% |
| Migdal Insurance & Financial Holdings Ltd.(3) | 78,690,320 | 6.10% |
| Harel Insurance Investments & Financial Services Ltd. (4) | 70,590,979 | 5.47% |
| Altshuler Shaham Ltd. (5) | 64,691,143 | 5.01% |
| The Phoenix Holdings Ltd. (6) | 64,690,757 | 5.01% |

Thepercentages shown are basedon 1,289,881,389Ordinary Shares issued and outstanding as of May 28, 2024 (after excluding shares held byus oroursubsidiaries).
Israel Corp. is a public company listed fortrading on the TASE.Based on the information provided by Israel Corp., Millenium Investments Elad Ltd. ("Millenium")andMr. IdanOferareconsideredas controllingshareholders jointlyofIsraelCorp.,forpurposesoftheIsraeliSecurities Law, 1968(the "IsraeliSecuritiesLaw")(eachofMilleniumandMr.IdanOferholdsharesinIsraelCorp.directly,andMr.IdanOferservesasadirectorofMillenium and has an indirect interest in it as the beneficiary of the discretionary trust that has indirect control of Millenium, as stated below). As of December 31, 2023, Millenium held approximately 44.71% of the issued share capital (and 45.14% of the voting rights) in Israel Corp., which heldasofDecember 31, 2023approximately43.98%ofthevotingrightsandapproximately43.15%oftheissuedsharecapitaloftheCompany.
TothebestofIsrael Corp.'s knowledge,MilleniumisheldbyMashat(Investments) Ltd.("Mashat")andbyXTInvestments Ltd.("XTInvestments"), with84.73%and15.27%holdingsinitsissuedsharecapital,respectively.MashatiswhollyownedbyAnsoniaHoldingsSingaporeB.V.("Ansonia") which is incorporated in theNetherlands.Ansonia is awholly owned subsidiary ofJelany CorporationN.V.(registered in Curaçao),which iswholly owned subsidiary ofthe Liberian company, CourtInvestments Ltd.("Court"). Courtiswholly owned by a discretionary trust, inwhich Mr. IdanOferis thebeneficiary.XTInvestments iswhollyownedbyXTHoldingsLtd.("XTHoldings").TothebestofIsraelCorp.'sknowledge,ordinaryshares ofXTHoldings areheld inequal sharesbyOronaInvestments Ltd.(whichis indirectly controlledby Mr.EhudAngel)and by LynavHoldings Ltd. ("Lynav"),which is controlled by adiscretionary trustinwhich Mr. IdanOferis the beneficiary. Mr. EhudAngelholds,among otherthings,a special share that grants him, inter alia, under certain limitations and for certain issues, an additional vote on the Board of Directors of XT Holdings. As of December 31, 2023, Lynav also held directly 1.26% of the issued share capital (and 1.27% of the voting rights) of Israel Corp. In addition, Kirby Enterprises Inc., which is to the best ofIsrael Corp.'s knowledge, indirectly held by the same trustthat holds Mashat, inwhich, as stated, Mr. Idan Ofer is the beneficiary, holds approximately 0.75% of the issued share capital and voting rights of Israel Corp. Furthermore, Mr. Idan Ofer held directlyapproximately3.93%oftheissuedsharecapital(andapproximately3.97%ofthevotingrights)ofIsraelCorp. asofDecember31,2023. 3. Based solely upon and qualified in its entiretywith reference to a Schedule 13Gfiled by Migdal Insurance &FinancialHoldings Ltd.("Migdal") withtheSEConJanuary31,2024.AccordingtotheSchedule13G,ofthe78,690,320OrdinarySharesreportedasbeneficiallyownedbyMigdal (i) 78,690,320 Ordinary Shares are held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Migdal, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, (ii) 7,229,615 Ordinary Shares are held by companies for the
management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent votingandinvestmentdecisions,and(iii)0arebeneficiallyheldfortheirownaccount(Nostroaccount).
Based solely upon and qualified in its entirety with reference to a Schedule 13G/A filed by Harel Insurance Investments & Financial Services Ltd. ("Harel"), with the SEC on January 30, 2024. According to the Schedule 13G/A, of the 70,590,979 Ordinary Shares reported as beneficially owned byHarel(i) 67,917,056Ordinary Shares are held for members ofthe public through, among others, providentfunds and/ormutualfunds and/or pension funds and/or index-linked securities and/or insurance policies, which are managed by subsidiaries of Harel, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, (ii) 1,962,970 Ordinary Shares are held by third-party client accounts managed by a subsidiary of Harel as portfolio managers, which subsidiary operates under independent management and makes independent investment decisions and has no voting power in the securities held in such client accounts, and (iii) 710,953OrdinarySharesarebeneficiallyheldforitsownaccount.
Based solely upon and qualified in its entirety with reference to a Schedule 13G filed by Altshuler Shaham Ltd. ("Altshuler"), with the SEC on January 17, 2023. According to the Schedule 13G, ofthe 64,691,143 Ordinary Shares reported as beneficially owned by Altshuler (i) 61,312,442Ordinary Shares are held by provident and pension funds managed by Altshuler Shaham Provident & Pension Funds Ltd., a majority-owned subsidiary of Altshuler, (ii) 3,378,702 Ordinary Shares are held by mutualfunds managed by Altshuler Shaham Mutual Funds Management Ltd., a wholly-owned subsidiary of Altshuler; and (iii) 263,100Ordinary Shares are held by hedge funds managed byAltshuler Shaham Owl, Limited Partnership, an affiliate of Altshuler-Shaham. Mr. Gilad Altshuler may be deemed to possess shared investment authority with respect to all of the foregoing Ordinary Shares due to his indirect 44.81% interestin Altshuler-Shaham, as well as his serving in various investment managementcapacities for Altshuler-Shaham and its subsidiaries and affiliates. The foregoing provident and pension funds, mutual funds and hedge funds, are managed for the benefit of public investors and not for the economic benefit of the foregoing reporting persons. Each of the foregoing reportingpersons lackauthoritywithrespecttothevotingofallof suchOrdinaryShares.
Basedsolelyuponand qualifiedinits entiretywithreference to a Schedule 13G/Afiledby ThePhoenixHoldings Ltd.("Phoenix"),withthe SEC on December 28, 2023.Accordingtothe Schedule13G/A,the64,690,757OrdinaryShares reportedthereinarebeneficiallyownedby variousdirector indirect, majority or wholly-owned subsidiaries of Phoenix (the "Phoenix Subsidiaries"). The Phoenix Subsidiaries manage their own funds and/ orthe funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or providentfunds, unit holders of mutual funds, and portfolio management clients. Each of the Phoenix Subsidiaries operates under independent management and makes itsownindependentvotingandinvestmentdecisions.

Ten directors are standing for re-election to the board of directors for a one-yearterm ending atthe next annual meeting of shareholders ofthe Company. Shareholders canvote for, or against, orwithhold their vote from, eachindividual nominee.
Each of the director nominees has confirmed that he or she complies with all requirements of a director under the Israeli Companies Law, possesses the necessary qualifications and is able to dedicate sufficienttime to fulfill his or her duties as a directoroftheCompany,takingintoconsiderationourcompany'ssizeandspecialneeds.
If elected atthe Meeting, non-executive directors (including our external directors, within the meaning ofthe Israeli Companies Law) will be compensated in accordance with the regulations promulgated under the Israeli Companies Law governing the compensation of external directors (the "Compensation Regulations"). In addition, if elected at the Meeting, the director nomineeswill continue to benefitfromthe indemnification, insurance and exemption agreements thatwe previously issued to them, as may be amended at the Meeting (see Proposal 4), and from directors' and officers' liability insurance as we shall procure from time to time. The Company also covers and/or reimburses its directors for expenses (including travel expenses) incurred in connection with meetings of the Board of Directors and its committees or performing other services for the Company in their capacity as directors, in accordance with the Company's Compensation Policy and the Compensation Regulations.See"SectionThree–CorporateGovernance"foradditionalinformation.
Dr. Miriam Haran was appointed to serve as external director(within the meaning of Israeli law) for an initialthree-yearterm on July14, 2021. Accordingly,Dr.MiriamHaranis standingforre-electionattheMeetingtoserveasanexternaldirectorforasecond three-year term. If elected at the Meeting, Dr. Haran will continue to serve as the chair of our HR & Compensation Committee andofourClimate,Sustainability&CommunityRelationsCommittee.
Dr. Haran has confirmed that she complies with all requirements of an external director under the Israeli Companies Law, possesses the necessary qualifications and is able to dedicate sufficient time, to fulfill her duties as an external director. ICL's Board of Directors determined that Dr. Haran is an independent director under the rules of the NYSE. In addition, the Board of Directors has determined that Dr. Haran qualifies as an "expert external director", as defined in regulations promulgated under theIsraeliCompaniesLaw.
If elected at the Meeting, Dr. Haran will be compensated according to the fixed annual and per meeting fees payable to an expert external director under the Compensation Regulations. In addition, if elected, Dr. Haran will continue to benefit from the indemnification, insurance and exemption agreement that we previously issued to her, as may be amended at the Meeting (seeProposal 4), and from directors' and officers' liability insurance as we shall procure from time to time. The Company also coversand/or reimburses its directors, including external directors, for expenses (including travel expenses) incurred in connection with meetings of the Board of Directors and its committees or performing other services for the Company in their capacity as directors, in accordance with the Company's Compensation Policy and the Compensation Regulations. See "Section Three – CorporateGovernance"foradditionalinformation.
Our Board of Directors recommends a vote FOR the re-election of Dr.Haran toserveasanexternaldirectorforasecondthree-year term.
Underthe Israeli Companies Law,the Israeli Securities Lawandthe Israeli CompetitionLaw, anIsraeli companymay exculpate, indemnify and insure its directors and officers against certain liabilities and expenses incurred for acts performed by them as directors and officers of the company, subject to certain limitations, and in each case provided that a provision authorizing such exculpation,indemnificationandinsuranceiscontainedinitsarticlesofassociation.
Our current Articles of Association allow us to exculpate, indemnify and insure our office holders (as defined in he Israeli Companies Law) for liabilities and expenses imposed on them as a consequence of an act which was performed by virtue of being an office holder ofthe Company (within the meaning ofthe Israeli Companies Law),to the fullest extent permitted by the Israeli Companies Lawand the Israeli Securities Law; however,they do not currently allowforindemnification and insurance of directors and officers in accordance with the Israeli Competition Law. Under the Israeli Competition Law, a company may indemnify or insure an officer or director for reasonable expenses (including legal fees) incurred as a result of a proceeding instituted against such officer or director under the Israeli Competition Law. We therefore propose to amend our Articles of Association in order to expand the indemnification, exemption and insurance provisions to allow us to indemnify and insure our directorsandofficerstothefullestextentpermittedbytheIsraeliCompetitionLaw.
ThefulltextoftheproposedamendmentstotheArticlesofAssociationisannotatedontheArticlesofAssociationattached hereto as Annex "A". The summary above is qualified in its entirety by reference to the full text of the annotated Articles of AssociationattachedheretoasAnnex"A".
OurBoardofDirectorsrecommendsavoteFORtheapprovalof the amendmentof theCompany'sArticlesofAssociation
Subject to shareholder approval at the Meeting of the proposed amendments to the Articles of Association (see Proposal 3), we further propose to amend the exemption, insurance and indemnification undertaking letter (the "Indemnification Undertaking") issued by the Company to each of its directors and officers to allow the Company to indemnify its directors and officers for expenses, including reasonable litigation expenses and legal fees, incurred by the director or officerin his/her capacity as an officer holder of the Company as a result of proceedings conducted under the Competition Law. If the shareholders shall not approve the proposed amendments to the Articles of Association (under Proposal 3) and/or the Indemnification Undertaking (under this Proposal 4), the existing Indemnification Undertakings issued by the Company to its directors and officers shall remaininfullforceandeffect.
The full text of the proposed amendments to the Indemnification Undertaking is annotated on the Indemnification Undertaking attached hereto as Annex "B". The summary above is qualified in its entirety by reference to the full text of the annotated Indemnification Undertaking attached here to asAnnex"B".
Our Board of Directors recommends a vote FOR the approvalof theamendment totheexemption, insuranceandindemnificationundertakingletterissuedby theCompanytoeachofitsdirectorsandofficers.

Pursuant to the approval and recommendation of our Audit and Accounting Committee and Board of Directors, the shareholders will be asked to approve the reappointment of Somekh Chaikin, a Member Firm of KPMG International ("KPMG"), independent certified public accountants in Israel, as our independent auditor until the next annual general meeting of the shareholdersoftheCompany.
OurBoardofDirectorsrecommendsavoteFORthere-appointmentofSomekh Chaikin,aMemberFirmofKPMGInternational,astheindependentauditorsof the CompanyuntiltheCompany'snextannualgeneralmeetingofshareholders.
Our Pre-Approval for Audit and Non-Audit Services Policy specifies the scope of permitted non-audit services provided by our external auditor so that its independence is not compromised by other services. All audit and permitted non-audit services provided by our external auditor are pre-approved by our Audit and Accounting Committee. All services performed by our auditor in 2023 complied with our Pre-Approval for Audit and Non-Audit Services Policy and professional standards and securitiesregulationsgoverningauditorindependence.
In accordance with our Articles of Association, our Board of Directors has the authority to determine the fees paid to our independent auditor. As contemplated by the Sarbanes-Oxley Act of 2002, our Board of Directors has delegated this authority toourAuditandAccountingCommittee.
| CATEGORY | 2023 2022 US\$ THOUSANDS |
1. Audit fees are the aggregate fees billed or expected to be billed for the audit of our annual financial statements. This category also includes services that are generally provided by the independent accountant, such |
|||||
|---|---|---|---|---|---|---|---|
| Audit Fees(1) | 3,963 | 4,468 | as consentsandreviewofdocuments filedwiththe SEC. | ||||
| Audit-Related Fees(2) | 30 | 377 | 2. Audit-related fees are the aggregate fees billed for assurance and relatedservices renderedduringtheyearsendedDecember31,2023and 2022,that are reasonably related to the performance ofthe audit and are |
||||
| Tax Fees(3) | 1,262 | 822 | notreportedunderauditfees. | ||||
| Total | 5,255 | 5,667 | 3. Tax fees are the aggregate fees billed for professional services rendered during the years ended December 31, 2023 and 2022, for tax compliance, tax advice, and tax planning, assistance with tax audits and appeals. |
The following table sets out the following fees for professional services billed by KPMG for services rendered in each of the respectiveyears:
At the Meeting, the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2023, which are included in the 2023 Annual Report, will be presented. The SEC maintains a website that contains reports, proxy and information statements and other information that we file electronically with the SEC at http://www.sec.gov. These SEC reports are also available on our website at www.icl-group.com under "Investors—Reports—Financial Reports". Shareholders may requestto receive paper copies at no charge by submitting a requestin writing to our Corporate Secretary atthe following address:MillenniumTower, 23AranhaStreet,P.O.Box 20245, TelAviv,6120201, Israel,Attention: Corporate Secretary
Any shareholder of the Company who intends to present a proposal at the 2024 Annual General Meeting of Shareholders must satisfy the requirements of the Israeli Companies Law and regulations thereunder. Any such shareholder(s) may presentproposals for consideration at the Meeting by submitting their proposals in writing to our Corporate Secretary at the following address: Millennium Tower, 23 Aranha Street, P.O. Box 20245, Tel Aviv, 6120201, Israel, Attn.: ICL Corporate Secretary, no later than June 6,2024.

Other than as set forth above, we are not aware of any other business to be transacted at the Meeting. If any other matters are properly presented at the Meeting, Ordinary Shares represented by executed and unrevoked proxies will be voted by the persons named in the enclosed form of proxy upon such matters in accordance with the judgment and recommendation of theBoardofDirectors.


At ICL, enterprise risk management ("ERM") is deeply ingrained within our corporate culture, serving as a foundational framework essential for anticipating and effectively navigating uncertainties, risks, and opportunities. Recognizing the inherent presence of risk across all aspects of our operations, we prioritize robust risk management as a cornerstone of sound corporate governance. A well-executed risk management strategy not only helps us achieve our objectives but also enhances our decision-making processes, ensures compliance with regulatory requirements and internal policies, and provides assuranceregardingtheeffectivenessofourcontrol.
Ourrisk governance structure, and the defined roles and responsibilities for key functions, is based on the "3 lines of defense" model. Our Board of Directors and respective committees, are highly committed to ensuring that risk management is implemented across ICL, overseeing the effectiveness of our risk framework. Their oversight includes monitoring pivotal corporate risks, aligned with our risk appetite, ensuring they align with our strategic objectives and values and monitoring theirmitigation plans.Underthe guidance of our CEO, our dedicated Global Executive Committee (GEC)takes direct ownership and is responsible forthe direct oversight of enterprise risk management, ensuring thatICL's risk managementframework is implemented, risk management responsibilities are delegated, and that risk management is integrated into all business activities. Furthermore,the GEC periodically reviews and approves ICL's corporate risk registerreports and updates ofrisks and mitigationplans,andemergingrisks.
In2023,ICLappointedadedicatedEVPasChiefRiskOfficer.TogetherwiththeGlobalRiskDirector,theyserveasasecondlineof defense, comprising a professional global function. Furthermore, each division has a dedicated Risk Leader promoting all risk activitieswithindivisions,inaccordancewithERMroutines.
Our governance structure is designed to effectively cascade our ERM process throughout our entire organization, combining top-down and bottom-up approaches. This ensures that all units, regardless of their geography and size, deploy the same process, utilizing identical taxonomy and assessment criteria. This approach enables us to maintain a holistic view of the entire ICL risk profile. Our global policy that outlines our ERM vision, commitment,risk governance,risk appetite,routines, and processes,whicharereviewedannually.
The approval of our director's compensation is governed by Israeli law. Under the Israeli Companies Law, compensation of directors generally requires the approval of the Company's HR & Compensation Committee, the Board of Directors and the shareholders, in that order. Generally,the approval oftheHR &Compensation Committee and the Board ofDirectors must be in accordance with the Company's compensation policy, except in special circumstances and subject to certain conditions, in whichcasetheshareholderapprovalmustbebyaspecialmajority.
Each of our non-executive directors (including our external directors, within the meaning of the Israeli Companies Law) are compensated in accordance with the Compensation Regulations. The Compensation Regulations set minimum and maximumamounts of cash compensation (anannualfee and per meeting fees), depending on the Company's shareholders' equity.
Generally, shareholder approval is notrequired for director compensation payable in cash (annual and per meeting fees) up to themaximumamountssetforthintheCompensationRegulations.
The per meeting fees vary in accordance with the qualification of the non-executive directors, depending on whether the director is qualified as an "Expert Director" underthe Compensation Regulations.Thefeesarecurrentlyas follows:
| EXPERT DIRECTORS | NON-EXPERT DIRECTOR | ||
|---|---|---|---|
| US\$ | |||
| Fixed Annual Fee | approximately 44,000 |
||
| Per Meeting Fee | approximately1,672 | approximately1,254 |
The Company also covers and/or reimburses its directors for expenses (including travel expenses) incurred in connection with meetings of the Board of Directors and its committees or performing other services for the Company in their capacity as directors, in accordance with the Company's Compensation Policy and the Compensation Regulations. Our Board members also benefit from directors' and officers' liability insurance and indemnification and exemption arrangements entered into withthem. Forfurtherinformation, see "Item6 –Directors, Senior Management and Employees – C. Board Practices – Insurance andIndemnification"inthe2023AnnualReport.
The aggregate compensation paid by us to our non-executive directors for the year ended December 31, 2023, was approximately \$840,000. This amount includes annual and per meeting fees but does not include business travel and expenses reimbursedtodirectors.
The following table sets out the approximate compensation earned by each individual who served as a non-executive director duringtheyearendedDecember31,2023(amountsexcludeVAT):
| FIXED ANNUAL FEE | AGGREGATE PER MEETINGFEES |
TOTAL | ||
|---|---|---|---|---|
| US\$ | ||||
| AviadKaufman | 43,509 | 37,120 | — | 80,628 |
| AvisarPaz | 43,509 | 34,110 | — | 77,619 |
| DafnaGruber | 43,509 | 45,146 | — | 88,654 |
| GadiLesin | 43,509 | 44,142 | — | 87,651 |
| LiorReitblatt | 43,509 | 46,149 | — | 89,658 |
| Michal Silverberg | 43,509 | 28,091 | 4,523 | 76,122 |
| Dr.MiriamHaran | 43,509 | 55,178 | — | 98,687 |
| OvadiaEli (2) | 11,735 | 7,775 | — | 19,510 |
| ReemAminoach | 43,509 | 22,071 | — | 65,580 |
| SagiKabla(3) | 43,509 | 46,818 | — | 90,326 |
| TzipiOzer-Armon | 43,509 | 21,402 | — | 64,911 |
Includes business travel and expenses.
Mr.EliconcludedhistenureasanICL directoronMay 10, 2023.
Mr.Kabla,IsraelCorp.'sChiefFinancial Officer, has requested that his director cash compensation be assigned and paiddirectly to Israel Corp. Foradditional details see "NON-EXECUTIVE DIRECTORS" above.
Mr. Doppelt's compensation terms as our Executive Chairman of the Board were approved by the Company's HR & CompensationCommitteeandBoardofDirectorsonJanuary31, 2022andFebruary8, 2022,respectively,andbyour shareholdersat the Annual General Meeting held on March 30, 2022. Mr.Doppelt's compensation terms are in effectforthree years fromJuly 1, 2022,andhiscompensationtermsareasfollows:
| Annual Cost | Annualfixed cost of employment ofNIS 1,800,000 (approximately \$489,000) | ||||||
|---|---|---|---|---|---|---|---|
| Short-Term Incentive | Entitlement to an annual cash bonus, calculated according to the short-term incentive ("STI") formula setforthintheCompany'sCompensationPolicy. Target STI- NIS 1,200,000 (approximately \$331,000). Maximum STI - NIS 1,200,000 (approximately \$331,000). Fordetails regarding Mr.Doppelt's STIformulaaswellas forthe 2023 STIpayout, seebelow"Short-Term |
||||||
| TerminationArrangement | Incentive–TheAnnualBonusComponent" Six-month adjustment period and six-month advance notice period |
||||||
| GRANT FORYEAR |
GRANT | TYPE | DATESOFGOVERNANCEBODIES' APPROVALS |
GRANTVALUE(ILS) | AMOUNT OF OPTIONS |
EXPIRATION DATE |
|
| 2022-2024 | March 30, Options 2022 |
HR & Comp. Committee 31.1.22 & 6.2.22 |
9 million (3 million |
1,055,100 | March 30, 2027 | ||
| Board 8.2.22 |
perannum) | ||||||
| Shareholders (Annual GM) 30.3.22 |
Theoptionswillvestinthreeequaltranches,uponeachofthethreeanniversariesofthegrantdate.OptionsfullyaccelerateifMr. Doppeltceasestoprovideserviceswithin12monthsfollowingachangeofcontrol(otherthanintheeventofterminationforcause).
The design and philosophy of our executive compensation program closely links financial performance and strategy execution resultingawards,supportingoureffortstoattract,motivateandretainthebrightesttalentwithskillsacrossadiverserange ofcapabilities. An emphasis on long-term incentives (equity-based compensation) focuses our executives on long-term success and aligns compensation with shareholders' interests. The compensation structure is designed to support the delivery of financial performance while demonstrating a commitment to operating safely, reliably and in a manner that is proactively consistentwithourEnvironmental,SocialandGovernance(ESG)commitments.
ESG performance targets are regularly included as part of the annual short term incentive plan of all executive officers, to reflect our commitment to create impactful solutions for humanity's greatest sustainability challenges. Accordingly, for 2023, our HR & Compensation Committee and Board of Directors set annual key performance indicators ("KPIs") for our executive management, that incorporate improvement of specific ESG targets, including: health & safety performance (IR improvement targets), environmental performance (water savings, waste reduction, greenhouse gas ("GHG") emissions reduction targets, aimed to eventually achieve science based targets, as further detailed in "Item 4 – Information On The Company — B. Business Overview - Task Force on Climate-related Financial Disclosures (TCFD)" of the 2023 Annual Report), suppliers sustainability performance (related to TfS/Ecovadis assessments), climate-change and climate related disclosures and rankings, diversity andgender equality improvementtargets, energy efficiency, green products, product carbon footprints calculations, and more.
The aggregate compensation amount incurred by us with respect to all of the members of our senior management (Global ExecutiveCommittee–GEC)asofDecember31,2023,wasapproximately\$12millionfortheyear2023.Thisamountincludesan annualprovisionforpensionorotherretirementbenefits forour seniormanagementofapproximately \$1million.
In 2023,the Company adopted a Compensation Recoupment Policy as required under, and in accordance with,the requirements ofSection10DoftheSecuritiesExchangeActof1934,asamended,andSection303A.14oftheNYSEListedCompanyManual. Effective as of October 2, 2023,this policy requires us to reasonably promptly recoverincentive-based compensation received by executiveofficersintheeventofcertainrestatementsoftheCompany'sfinancialstatementsduetomaterialnoncompliance with any financial reporting requirement under U.S. federal securities laws. The amount to be recovered under this policy is calculated(ona pre-tax basis) based onthe excess ofthe amountreceived by the executive officer overthe amountthat would have been received had the amount been calculated based on the restated financial statements. A copy of this policy is attachedasExhibit4.7tothe2023AnnualReport.
DETAILS OF THE RECIPIENT PAYMENTSFORSERVICES NAME POSITION SCOPEOF POSITION BASE SALARY COMPENSATION (1) BONUS (STI)(2) EQUITY BASED COMPENSATION(LTI)(3) TOTAL US\$THOUSANDS RavivZoller President&Chief ExecutiveOfficer 100% 805 1,157 668 1,852 3,677 YoavDoppelt Executive Chairman oftheBoard Invests significant portionofhis time 411 491 219 1,007 1,717 EladAharonson President, Growing SolutionsDivision 100% 402 566 233 561 1,350 AviramLahav Chief Financial Officer 100% 383 550 237 446 1,233 LilachGeva-Harel EVP, Chief Legal and Sustainability Officer 100% 263 405 176 369 950
The following table and accompanying notes describe the compensation incurred forthe year 2023 with respectto the five highestearningseniorofficersofICLforsuchperiod,asprovidedinthe2023AnnualReport.
base salary, customary social benefits, customary social and related provisions, Company car and reimbursement of telephone expenses. The compensation is inaccordancewiththeCompany'sCompensationPolicy.
The annual bonuses (STI awards)to officer holders for 2023, including the top-five earners in 2023,were approved by ourHR& Compensation Committee and Boardof DirectorsonFebruary11,2024andFebruary13,2024,respectively.
The expense for share-based payment compensation is calculated according to IFRS and is recognized in the Company's statement of income over the vesting period of each part of the grant. The amounts reported in this column represent the expense recorded in the Company's financial statements for the year ended December 31, 2023 (the "Audited Financial Statements") included in the 2023 Annual Report, with respectto equity-based compensation granted to the senior officer. Fordetails regardingtheCompany'sequitycompensationplans, seeNote19toourAuditedFinancialStatements.
Fivehighestearningseniorofficers'employmenttermssummary,accordingtotheiremploymentagreements:
| #FN | SENIOR OFFICER | EMPLOYMENTTERMS |
|---|---|---|
| 1. | RavivZoller | OnApril18,2023andApril20,2023,ourHR&CompensationCommitteeandBoardofDirectors,respectively,approvedan immaterial amendment to Mr. Zoller's compensation terms, as included in his employment agreement from July, 2018(andamendedinJuly 2019)("Mr.Zoller'sEmploymentAgreement"),exercisingtheirauthorityasgrantedunder Section 272(d) of the Israeli Companies Law, which permits a non-material amendment to an existing transaction solely with the approval of the Compensation Committee (the "Immaterial Amendment") inasmuch that the amendment complies with the Company's Compensation Policy. The Immaterial Amendment resulted in an increase ofapproximately9.2%inMr.Zoller'soverallcompensationterms,asofDecember31,2023,areasfollows: Base salary: - Annual base salary of ~NIS 3.1 million (approximately \$841,000), or - Monthlybase salaryof ~NIS 258,000(approximately\$70,000). STI – Annual Bonus: Mr. Zoller's STI target is ~NIS 3.4 million (approximately \$937,000), as of December 31, 2023. Mr. Zoller's maximum STI is ~NIS 4.4 million (approximately \$1.2 million). For information regarding Mr. Zoller's STIformula, performanceandpayoutin2023, seebelow"Short-TermIncentive -TheAnnualBonus Component". LTI – Equity: There was no change to Mr. Zoller's LTI component under the Immaterial Amendment. Mr. Zoller is entitledtoanannual LTI(equity)grantofNIS 5.3million(approximately \$1.5million),oranyotheramountper vesting annum, as determined and approved by the Company's authorized governance bodies, including by the Company's shareholders.OnFebruary6,2022,February8,2022,andMarch30,2022,ourHR&CompensationCommittee,Board of Directorsandshareholders,respectively,approvedathree-year LTIawardtoMr.Raviv Zoller,fortheyears 2022- 2024, in the form of non-marketable options, with value of NIS 5.5 million (approximately \$1.5 million) per vesting annum. For details regarding Mr. Zoller's equity-based compensation grants, see Note 19 to our Audited Financial Statements; Terminationarrangements:therewasno change toMr.Zoller's terminationtermsunderthe ImmaterialAmendment,whichremainas follows: - 12-months advance notice period in case oftermination by the Company (notfor cause) or 6-months advance noticeincaseofresignation; - Additional severance equalto the last base salary multiplied by the number of years that Mr. Zoller served as ICL's President&CEO. In accordance with Mr. Zoller's Employment Agreement, all compensation items per Mr. Zoller's Employment Agreement,areindexedtotheIsraeliConsumerPriceIndex(CPI). |
| TheImmaterialAmendment complieswithalloftheCompany'sCompensationPolicy requirements. Allother cash and non-cash benefits payable to our senior executivespursuantto our policies in effectfrom time to time, including but not limited to, pension, study fund, disability insurance, Company car, gross up, etc., as well as the exemption, insuranceand indemnificationarrangementsapplying tothe Company's officeholders. |
||
| 2. | YoavDoppelt | For details regarding Mr. Doppelt's compensation terms as our Executive Chairman of the Board, see above 'Executive Chairman ofthe Board's Compensation', as well as the Short-Term Incentive (Annual Bonus) Component sectionbelow. |
| 3. | Elad Aharonson | Monthlybasesalary:~NIS125,000(approximately\$34,000),asofDecember31,2023.Mr.Aharonson'sbasesalary may be updated twice a year according to the rise in the CPI in the months that have passed since the previous update. 2023STI:Mr.Aharonson'stargetSTIis75%ofhisannualbasesalary.FordetailsregardingMr.Aharonson'sSTI performanceandpayoutin2023, seebelow"Short-TermIncentiveAnnualBonusComponent". LTI: The equity-based compensation amountin the above table reflects the expense that was recognized for Mr. Aharonson'sLTIintheCompany's2023FinancialStatements. Terminationarrangements:Advancenoticeperiodof6months. All other benefits customary in the Company, such as regular provisions for pension and severance, disability fund, Company car, gross up, as well as the exemption, insurance and indemnification arrangements applying to the Company'sofficeholders. |

| #FN | SENIOR OFFICER | EMPLOYMENTTERMS |
|---|---|---|
| 4. | Aviram Lahav | OnFebruary 14and16, 2023,ourHRandCompensationCommitteeandBoardofDirectors,respectively,approveda change to Mr. Lahav's compensation mix, such that as of March 2023, Mr. Lahav's compensation terms are as follows: Monthlybasesalary:~NIS122,000(approximately\$33,000),asofDecember31,2023.Mr.Lahav'sbasesalarymaybe updated twice a year according to the rise in the CPI in the months that have passed since the previous update. 2023STI:Mr.Lahav's targetSTIis 75%ofhisannualbasesalary.Fordetails regardingMr.Lahav'sSTIperformanceand payoutin2023,seebelow"Short-TermIncentiveAnnualBonusComponent". LTI: The equity-based compensation amountin the above table reflects the expense that was recognized for Mr. Lahav'sLTIintheAuditedFinancialStatements. Terminationarrangements:advancenoticeperiodof6months. All other benefits customary in the Company, such as regular provisions for pension and severance, disability fund, Company car, gross up, as well as the exemption, insurance and indemnification arrangements applying to the Company'sofficeholders. |
| 5. | LilachGeva-Harel | Monthlybasesalary: ~NIS82,000(approximately\$22,000),asofDecember31, 2023.Mrs.GevaHarel'sbasesalary may be updated twice a year according to the rise in the CPI in the months that have passed since the previous update. 2023STI:Mrs.GevaHarel'stargetSTIis75%ofherannualbasesalary.FordetailsregardingMrs.GevaHarel'sSTI performanceandpayoutin2023, seebelow"Short-TermIncentiveAnnualBonusComponent". LTI: The equity-based compensation amount in the above table reflects the expense that was recognized for Mrs. GevaHarel'sLTIintheAuditedFinancialStatements. Terminationarrangements:Advancenoticeperiodof6months. All other benefits customary in the Company, such as regular provisions for pension and severance, disability fund, Company car, gross up, as well as the exemption, insurance and indemnification arrangements applying to the Company'sofficeholders. |
Our Annual Short Term Incentive Plan is a key element in supporting our pay-for-performance philosophy. Each Executive Officer's annual incentive opportunity is determined by performance in certain components, with an emphasis on key operating andfinancialmetrics,includingESGtargets.
The Annual Incentive Plan for 2023 continued to include strategic metrics at both ICL and operating segmentlevels to measure andrewardinitiatives criticaltothelonger-termsuccessoftheorganization.Theincentivetargets continue to be set as a percentage of salary for most executives, with actual payouts based on a performance multiplier dependentontheachievementofpredeterminedannualgoals.
ESG performance targets are included as part of the annual short term incentive plan of all executive officers, to reflect our commitment to create impactful solutions for humanity's greatest sustainability challenges, including: health & safetyperformance (IR improvement targets), environmental performance (water savings, waste reduction and GHG emissions reduction targets, aimed to eventually achieve science-based targets (SBTi)), suppliers sustainability performance (relatedto TfS/Ecovadis assessments), climate-change and climate related disclosures and rankings, diversity and gender equality
improvementtargets, energy efficiency, greenproducts, product carbonfootprints calculations, andmore.OnFebruary 11, 2024 and February 13, 2024, ourHR&Compensation Committee andBoard ofDirectors,respectively, approved the annual short-term incentiveawards toour officeholders for 2023, including the top-five earners in2023 amongICL's senior officers, inaccordance with theCompany'sCompensationPolicy,andaccordingtothecriteriasetforthabove.

Our Annual Short Term Incentive Plan is a key element in supporting our pay-for-performance philosophy. Each Executive Officer's annual incentive opportunity is determined by performance in certain components, with an emphasis on key operating and financial metrics,includingESGtargets.
The Annual Incentive Plan for 2023 continued to include strategic metrics at both ICL and operating segmentlevels to measure and rewardinitiatives criticaltothelonger-term successoftheorganization.Theincentivetargets
continue to be set as a percentage of salary for most executives, with actual payouts based on a performance multiplier dependent on theachievementofpredeterminedannualgoals.
ESG performance targets are included as part of the annual short term incentive plan of all executive officers, to reflect our commitment to create impactful solutions for humanity's greatest sustainability challenges, including: health & safety performance (IR improvement targets), environmental performance (water savings, waste reduction and GHG emissions reduction targets, aimed to eventually achieve science-based targets (SBTi)), suppliers sustainability performance (related to TfS/Ecovadis assessments), climate-change and climate related disclosures and rankings, diversity and gender equality improvement targets, energy efficiency, green products, product carbon footprints calculations, and more. On February 11, 2024 and February 13, 2024, our HR & Compensation Committee and Board of Directors, respectively, approved the annual short-term incentive awards to our office holders for 2023, including the top-five earners in 2023 among ICL's senior officers, in accordancewith the Company's Compensation Policy, and according to the criteria setforthabove.
> The STI Target for the CoB represents the conceptual payout amount for 100% performance level (i.e., achieving weighted 100% of all targets)inagivenyear.TheSTITargetfortheCoBshallnotexceed120%oftheCoB'sannualbasesalary.
> STI Threshold: If either ICL's adjusted operating income and/or adjusted net income actual performance, as adjusted according to the pre-defined profit adjustments list that is listed in the Compensation Policy (the "Predefined List"), will not meet the threshold performancelevel(60%ofbudget),therewillbenopayoutundertheCoBSTIplanatall.
> 30% of the CoB's STI Target will be measured against the performance level of ICL EBITDA; 30% against the performance level of ICL Operating Income; 20% againstthe performance level of ICL NetIncome, and 20% againstthe performance level of ICL's Revenues. These goals will be taken from ICL's budget for the relevant fiscal year, and each will be measured as adjusted according to the rating scale set forth in the Company's Compensation Policy. Such financial goals are calculated according to the figures from ICL's annual reports, as adjustedinaccordancewiththePredefinedList.
> Mr.Doppelt'sSTITarget,whichisalsohismaximumSTIpayoutinanygivenyear,isNIS1.2million(approximately\$331,000).
> Themaximum STI payoutforthe CoBshall not exceed,for any given fiscal year,the lower of150% ofthe CoB's STI Target and \$1million. For details regarding Mr. Doppelt's STI payout in 2023, see the five-highest earners STI payout in 2023 section below.
> The target STI ("STI Target") for the CEO represents the conceptual payout amount for 100% performance level (i.e., achieving weighted 100%ofalltargets)inagivenyear.TheSTITargetfortheCEOshallnotexceed120%oftheCEO'sannualbasesalary.
> STI Threshold: If eitherICL adjusted operating income and/or adjusted netincome actual performance, as adjusted according to the predefined profit adjustments listed in the Compensation Policy (the "Predefined List"), will not meet the threshold performance level (60% of budget),there will be no payoutforthe 80% of STIthatis measured against measurable financial and measurable non-financial goals.
> 80% of the CEO's STI Target will be measured against the performance level of annual measurable financial and measurable nonfinancial goals determined by the HR & Compensation Committee and the Board of Directors at the beginning of each fiscal year, as detailedintheCompensationPolicy,andincludingESGtargets,asdetailedabove.
> Out of the 80% STI Target, at least 60% of the STI Target will be measured against financial goals that will be included in the annual budget. The other 20% (orless) ofthe STI Target will be measured against other measurable non-financial goals. The achievementlevelof each goal, whether measurable financial goals or measurable non-financial goals, will be measured independently of other goals, according to the rating scale set forth in the Compensation Policy, and then translated to payout factors. The measurable financial goals are calculatedaccordingtothe figures fromICL'sannualreports,asadjustedinaccordancewiththePredefinedList.
> The remaining 20% ofthe CEO's STI Target will be measured based on a qualitative evaluation by the HR & Compensation Committee and Board of Directors after receiving a recommendation of the Executive Chairman of the Board. The maximum payout for this component cannotexceedthehigherofthreebasemonthlysalariesor25% oftotalactualSTIpayout.
> The maximum STI payout for the CEO pursuant to the Company's Compensation Policy cannot exceed, for any given year, the lower of 130%of theCEO'sSTITarget forsuchyearand\$1.5million.
> Mr.Zoller's STITargetafteradjustmentoflinkage tothe CPIasperMr.Zoller's employmentagreement, isNIS 3.4million(approximately \$937,000),asofDecember2023andhismaximumSTIpayout isNIS4.4million(approximately\$1.2million).
Fordetails regardingMr.Zoller'sSTIpayout in2023, see the five-highestearnersSTIpayout in2023 sectionbelow.

With respect to our Executive Officers, other than our CEO and CoB, the Company's Compensation Policy provides that the annual bonuses may be calculated by measurable financial metrics and/or measurable non-financial metrics, as pre-determined by our HR & Compensation Committee and Board of Directors, and/or a qualitative evaluation. The HR & Compensation Committee and Board of Directors may determine, in any given year,thatthe STI payoutfor such Executive Officers will be granted, in whole orin part, accordingto a qualitative evaluation of non - measurable items, subject to the maximum STI payout set forth in the Compensation Policy and describedbelow.
ThemaximumSTIpayoutforanExecutiveOfficers,otherthantheCEOandExecutiveChairman,shallnotexceed,foranygivenfiscalyear,the lowerof225%oftheExecutiveOfficer'sSTITargetforsuchyearand\$1,000,000. Fordetails regarding the highest earners ExecutiveOfficers STI payoutin 2023, see below.
| EXECUTIVE OFFICE | ANNUAL BASE (1) | STI TARGET % | STI TARGET | OVER ALL SCORE OF % TARGET(2) |
2023 STIPAYOUT |
|---|---|---|---|---|---|
| Raviv Zoller | 840 | NA(3) | 940 | 71.5% | 670 |
| YoavDoppelt | 410 | NA(4) | 330 | 66.2% | 220 |
| EladAharonson | 410 | 75% | 300 | 71.9% | 220 |
| AviramLahav | 410 | 75% | 300 | 78.2% | 240 |
| LilachGeva-Harel | 270 | 75% | 190 | 87.2% | 180 |
* Figures are translated to \$US currency and rounded to the nearest thousand which may cause immaterial calculation differences.
TheAnnualBaseamountsareasofDecember31,2023.
The adjustments to the Company's annual net and operating income, as specified in "Item 3 – Key Information – A. Selected Financial Data" ofthe 2023 Annual Report, for purposes of calculating the STI Threshold (as defined above) and for purposes of calculating the measurable financials goals for the CEO and the CoB, adhere to the Predefined List outlined in the Company's Compensation Policy, excluding the adjustment pertaining to charges related to the security situation in Israel, which was not adjusted forthe above purposes. Consequently,the adjusted net and operating income forthe above STI purposes is lowerthan the adjusted net and operating income, as reported. For all executive officers, otherthan Mr. Zoller(see footnote#3 below) and Mr. Doppelt who has a differentformula as set forth above,this column represents the weighted % score ofthe measurable financial and non-financial goals (including ESG targets) and qualitative evaluation. 3. Mr. Zoller's STI Targetwasdeterminedin Mr. Zoller's EmploymentAgreementas adollaramount only (linked to the CPI).
Mr.Doppelt's STI Target(being alsohismaximumSTI potential) per his employment agreementis set as a dollar amount only ofNIS 1.2million (approximately \$331,000).


According to our Articles of Association, we must have no less than seven and no more than 20 directors serving on our Board of Directors. Our Board of Directors is currently comprised oftwelve directors, including two external directors elected pursuant to the requirements ofthe Israeli Companies Law. A director who is not an external directoris elected annually and holds office until the next annual general meeting of shareholders following the general meeting at which such director was elected, or until his or her earlierresignationorremoval pursuantto aresolutionof a generalmeeting of shareholders or applicable law.
At the Meeting, all of our currently serving directors who are not external directors are standing for election, namely Yoav Doppelt,AviadKaufman,AvisarPaz, SagiKabla,ReemAminoach, LiorReitblatt,TzipiOzerArmon,Gadi Lesin,Michal Silverberg and Shalom Shlomo, each to hold office until the close of the next annual general meeting of shareholders and until each of their successors is duly appointed and qualified, unless any office is earlier vacated due to their earlier resignation or removal. All such director nominees were elected to serve as directors at our annual general meeting of shareholders held in 2023, other thanMr.ShalomShlomowhowasappointedtoserveasadirectorbyourBoardofDirectorsinJanuary2024.
Additionally, one of our external directors, Dr. Miriam Haran, is standing for re-election at the Meeting for a second three-year term.Our other external director, Ms.Dafna Gruber, will continue to serve in accordance with herthree-yeartermuntil January 27, 2025.
Following the Meeting, our Board of Directors will be comprised of twelve directors, including two external directorselected pursuanttotherequirementsoftheIsraeliCompaniesLaw.


Mr.Doppelt servesas theChiefExecutiveOfficerofIsraelCorp.PreviouslyMr.Doppelt servedas the Chief Executive Officer of Kenon Holdings Ltd., a global company (NYSE: KEN), and Executive Chairman of IC Power Ltd., a power generation company, from March 2014 to September 2017. Prior thereto, Mr. Doppelt was the founder and Chief Executive Officer of the Ofer Group's private equity fund where he was involved in numerous investments in the private equity and technology sectors. Mr. Doppelt has served as the Chief Executive Officer of XT Investments (formerlyknownasXTCapitalandOferHi-Tech) since2001.Mr.Doppelthas activelyledseveralpublicofferingsof equity and debt offerings in the US and Europe, and he has extensive operational and global business experience with growth companies. Mr. Doppelt also serves as a director of AKVA Group ASA and previously served as ChairmanofOPCEnergyLtd.(TASE:OPC),andasadirectorofZim IntegratedShippingServicesLtd.andofMelisronLtd.Mr.Doppelt holds a BA degree in Economics and Managementfrom the Technion – Israel Institute of Technology, and anMBAdegreefromHaifaUniversity.

Mr.Kaufmanis the Chief ExecutiveOfficer ofOneGlobeBusinessAdvisory Ltd,the chairmanofIsrael Corp., anda board member of KenonHoldings Ltd.,OPC Energy Ltd. and other private companies, each of which may be associatedwithMr.IdanOfer.From2017untilJuly2021,Mr.KaufmanservedastheChiefExecutiveOfficerof QuantumPacific (UK) LLPand from2008until 2017as Chief FinancialOfficerofQuantumPacific (UK) LLP(andits predecessor Quantum Pacific Advisory Limited). From 2002 until 2007, Mr. Kaufman fulfilled different senior corporate finance roles at Amdocs Ltd. Previously, Mr. Kaufman held various consultancy positions with KPMG. Mr. Kaufman is a certified public accountant and holds a BA degree in Accounting and Economics from the Hebrew University of Jerusalem(withdistinction),andanMBAdegreeinFinancefromTelAvivUniversity.

Mr.PazservedastheChairmanoftheBoardofDirectorsofOPCEnergyLtd.untilJanuary3,2021.Previously,Mr. Paz servedas theChiefExecutiveOfficerofIsraelCorp.andpriortothat,as theChiefFinancialOfficerofIsrael Corp.Mr. Paz received a BA degree in Economics and Accounting from Tel Aviv University and is a certified public accountantinIsrael(CPA).

Independent: external director under the Israeli Companies Law and independent under the NYSE rules
Ms. Gruber currently serves as the Chief Financial Officer of Netafim Ltd., a precision irrigation solutions company. Prior to joining Netafim, Ms. Gruber held Chief Financial Officer positions in various companies including Clal Industries from 2015 to 2017, Nice Systems Ltd. from 2007 to 2015, Alvarion Ltd. from 1999 to 2007. Ms. Gruber currently serves as an external director of Cellbrite Ltd. and served as an external director in various companies, mostrecently in Nova Measuring Instruments Ltd. until 2023. Ms. Gruberis a certified public accountant and holds aBAdegreeinAccountingandEconomics fromTelAvivUniversity.
Mr. Lesin served as President and CEO of Strauss Group Ltd. ("Strauss Group"), an international food and beverage company and the largest food company in Israel, from 2009 to 2018. Mr. Lesin successfully led the Strauss Group through a time of intense economic, global and social change. Under his leadership,the Strauss Group strengthenedits international operations, more than doubled its equity value, and grew its profits significantly. Mr. Lesin currentlyserves as a director in ORIAN SH.M. Ltd. and as an external director in Electra Consumer Products, both companies listed on the TASE. Mr. Lesin is the founder of and serves as a director of Wonder Veggies Ltd. Mr. Lesin holds a BAdegree in business management from the Tel Aviv College of Management and an MBA degree from Ben Gurion University.


Mr. Reitblatt served as Chief ExecutiveOfficer and Chairman ofthe Board of Super-Pharm (Israel) Ltd. Mr. Reitblatt has also previously served, among other positions, as Chairman ofthe Board of Life Style Ltd. and member ofthe board of Office DepotIsrael Ltd. Mr. Reitblattis a certified public accountant, and holds a BA degree in Accounting andEconomics fromTelAvivUniversityandanMBAdegreefromtheUniversityof California,Berkeley.
Independent: independent under NYSE rules and meets all qualifications under the Israeli Companies Law for IndependentDirectorbutwasnot formallyclassifiedasone
Ms. Silverberghas servedasa ManagingDirectorattheNovartisVenture Fund("NVF") since 2017.Priorto joining NVF and from 2014, Ms. Silverberg served as a Senior Partner at Takeda Ventures and, priorto that and from 2007,Ms. Silverberg worked at Novo Nordisk in roles of increasing responsibility, including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team. Since 1998, Ms. Silverberg has held positions in various sectors of the life science industry, including in the Office of the Chief Scientist ofIsrael (the incubator program), venture capital (Ofer BrothersHi Tech investing group) and global pharmaceutical and biotech companies, including various positions at MGVS Ltd., an Israeli biotech company, and at OSI Pharmaceuticals, Inc. in a business development role. Ms. Silverberg currently serves as a director in several private companies. Ms. Silverberg holds a B.A. degree in Economics and Business management from Haifa University, Israel,anM.B.A.degreefromTel AvivUniversity, Israel,andaMAdegreeinBiotechnology fromColumbia University,NewYork.

Dr. Haran has been involved in environmental management and safety issues for over forty years in various key positions. Dr. Haran is currently serving as chair of Israel Resource Efficiency Center – a knowledge and consulting center for reducing the environmental impact of industry by streamlining raw materials, energy, water, etc. Dr. Haran serves as chair ofthe Weitz Centerfor Sustainable Development and a board member of M.A.I – a majorIsraelirecycling company of electrical and electronic waste as well as the Chair ofthe public environmental committee at Maala. Dr. Haran previously served as Director General, Deputy Director General and Chief Scientist of Israel's Ministry of Environmental Protection, as well as the Head of Ono Academic College's MBA Program in Environmental Management.Dr.Haran has served in numerous scientific, corporate, and public organizations.Dr.Haran served as Chair of the Israel Consumer Council, Environmental Consultant, Board Member of The Environmental Services Company Ltd. (ESC), Board Member of BGN Technologies Ltd., and Member of the General Assembly of the Jerusalem Institute for Israel Studies. Dr. Haran was Senior Researcher at A.Y. Laboratories, Researcher at Unikoor Biotechnology, Researcher and Senior Lecturer at the Hebrew University, and Researcher at Rutgers University in Newark, New Jersey. Dr. Haran served as an external director of ICL between 2010-2018. Dr. Haran holds a B.Sc. in Natural Sciences from the Hebrew University of Jerusalem and a PhD in Organic Chemistry from Brandeis University.
Independent: independent under NYSE rules and meets all qualifications under the IsraeliCompaniesLaw for IndependentDirectorbutwasnot formally classifiedasone
Mr. Aminoach serves as the chair of the accountants' internship committee of the Israel Defense Forces ("IDF"). Mr. Aminoach served, until recently, as a director of Israel Aerospace Industries Ltd., in which he was the chair of the audit committee, the finance committee, and the risk management committee. Additionally, Mr. Aminoach was the founding partner ofthe accounting firm Shtainmetz Aminoach & Co. In his military service, Mr. Aminoach, a brigadier general, served as a member of the General Staff Forum of the IDF, Head of Budgets at the Ministry of Defense, Financial Advisor to the IDF Chief of Staff and Head of the IDF Budget Division. Previously, Mr. Aminoach served as director at Ofer Investments Ltd. and as director and Chairman ofthe Audit Committee at Zim Ltd., ofthe Israel Corp.group. Mr. Aminoach also served as a member ofthe Board of Governors ofHadassah Medical Center. Mr. Aminoach is a certified public accountant, and holds a BA degree in Accounting and Economics from Tel Aviv University (academichonors,Dean's honorlist)andMBAdegree inBusinessAdministrationfromTelAvivUniversity.


Mr.Kablahas servedas theChiefFinancialOfficerofIsraelCorp. sinceDecember 2015.Mr.Kablapreviously servedas director ofOilRefineries Ltd and as Senior Executive ofBusinessDevelopment, Strategy and IRat Israel Corp. PriortojoiningIsrael Corp., Mr.KablaheldvariousmanagementrolesatKPMGCorporate Finance andM&A. Mr.Kablaholds an MBA degree in Finance fromCOMAS and a B.A. degree in Economics and Accounting fromBar-IlanUniversity and heisqualifiedasacertifiedpublicaccountant(Israel).

Ms. Ozer-Armon serves as the Chief Executive Officer of Lumenis Ltd. Before joining Lumenis, Ms. Ozer-Armon headed the Japanese market activities of Teva Pharmaceutical Industries Ltd. and served as Senior Vice Presidentof Sales and Marketing at SanDisk. Previously, Ms. Ozer-Armon also served as VP & General Manager at MSystems. In addition to ICL, Ms. Ozer-Armon is a director at the Strauss Group Ltd., SimilarWeb Ltd. and Check Point Ltd. andpreviously served as a director atIACC and Itamar Medical Ltd. Ms. Ozer-Armon holds aBAdegree, magna cumlaude,in Economics, and an MBA degree in Finance and Marketing from Tel Aviv University, and she is an AMP graduate oftheHarvardBusinessSchool.

Mr. Shlomo has over twenty years of experience in various leading positions in the public and private sectors. Mr. Shlomo serves as the chairman ofthe Haim Avshalom Institute, since May 2023, and as a director of Ashdod RefineryLtd.,anIsraelipublic company, sinceAugust 2023.Aspartofhispositions inthe privatesector,Mr. Shlomoprovided consulting services to Israeli energy, infrastructure and telecommunications companies, among others. In addition, Mr. Shlomo servedinvarious senior positions in thepublic sector, includingas the Israeli Cabinet Secretary fromJune2021until January2023.Mr.Shlomoholds anLLBdegreeinlawfromtheIsraeliAcademicCenterforLawandBusiness.

As a public Israeli company, we are required by the Israeli Companies Law to have at least two external directors who meet certain independence criteria to ensure thatthey are notrelated to the Company orto our controlling shareholder. The definition of an "external director" or "independent director" under the Israeli Companies Law and the definition of an "independentdirector"undertheNewYork Stock Exchange ("NYSE")rulesarevery similar, andthus,wewouldgenerally expecta directorwho qualifies as one to also qualify as the other.However, since the definitions provided inIsraeli lawandU.S. lawarenot identical,itispossibleforadirectortoqualifyasonebutnotnecessarilyastheother.
An external director is required to have either financial and accounting expertise or professional qualifications, as defined in the relevant regulations promulgated under the Israeli Companies Law, and at least one of the external directors is required to have financial and accounting expertise. Our external directors, Ms. Dafna Gruber and Dr. Miriam Haran, have financial and accounting expertise as defined in such regulations. An external director is entitled to reimbursement of expenses and compensation as provided in the Compensation Regulations promulgated under the Israeli Companies Law but is otherwise prohibited from receiving any other compensation fromus, directly orindirectly, during his or hertermof office and fortwo years thereafter.
Under the Israeli Companies Law, external directors must be elected at a shareholders' meeting by a simple majority of the votes cast, provided that either of the following conditions is met: (i) such majority includes a majority of the votes cast by noncontrolling shareholders and shareholders who do not have a personal interest in the election (excluding a personal interest that did not result from the shareholder's relationship with the controlling shareholder), excluding abstentions, or (ii) the votes cast by noncontrolling shareholders and shareholders who do not have a personal interest in the election opposing the election (excluding a personal interest that did not result from the shareholder's relationship with the controlling shareholder) did not exceed2%ofouraggregate votingrights.Generally, externaldirectorsmay serve foruptothreetermsofthreeyears each, and as a company whose shares are traded on the NYSE, our Audit and Accounting Committee and Board of Directors may nominate external directors for additional three-year terms under certain circumstances for election by the shareholders by thesame majority required for election of an external director as described above. Even if an external director is not nominated by our Board of Directors for reelection for a second or third term, an external director may be nominated for reelection for up to two additional three year terms, by (a) one or more shareholders holding at least 1% of our voting rights (provided the external directoris not an "affiliated or competing shareholder", or a relative of such a shareholder, atthe time ofthe appointment, andisnot"affiliated"withsuchashareholderatthetimeoftheappointmentorwithinthetwoyearsprecedingthedate of appointment, as such terms are defined in the Israeli Companies Law), and in such circumstances,the reelection ofthe external director requires the approval of our shareholders by a majority of the votes cast by noncontrolling shareholders and shareholders who do not have a personal interest in the election (excluding a personal interest that did not result from the shareholder's relationship with the controlling shareholder and excluding abstentions) and the votes cast by such shareholders approving the reelection must exceed 2% of our aggregate voting rights; and (b) the external director him or herself, in which case the election by the shareholders is by the same majority required forthe initial election of an external director, as described above. The termof office of anexternal directormay be terminatedpriortoexpirationonlybyashareholder vote, by the same threshold required for election, or by a court, butin each case only ifthe external director ceases to meetthe statutory qualificationsforelectionoriftheexternaldirectorbreacheshisorherdutyoftrusttotheCompany.
Under the Israeli Companies Law, each committee of the Board of Directors that exercises power of the Board of Directors mustincludeatleastoneexternaldirectorandallexternaldirectorsmustbemembersoftheCompany'sAuditCommitteeand CompensationCommittee.
We have two external directors: Dr. Miriam Haran, whose first three-year term commenced on July 2021 and is standing for reelection at the Meeting for an additional three year term, and Ms. Dafna Gruber, whose first three-year term commenced on January 2022.
Our Board of Directors is committed to continuous improvement and recognizes the fundamental role a robust Board of Directors and committee evaluation process play in ensuring that our Board of Directors maintains optimal composition and functions effectively. In the annual self-evaluation process, the members of the Board of Directors conduct a confidential assessment of the performance, risk oversight and composition of the Board and its committees, as relevant. As part of the evaluation process, the Board of Directors reviews the effectiveness and overall composition of the Board of Directors, including director tenure, board leadership structure, diversity and skill sets, the quality and scope of the materials distributed in advance of meetings and the board's access to Company executives and operations, to ensure the Board of Directors serves the best interests of shareholders and positions the Company for future success. After the evaluations, the board and committees, in conjunction with the corporate secretariat function, work to improve upon any issues presented during the evaluation process and to identify opportunities that may lead to further improvement. While this formal self-evaluation is conducted on an annual basis, the evaluation process is an ongoing process throughout the year. Directors continuously share their perspectives, feedback,andsuggestions throughouttheyear,whetherduringtheboard'sexecutivesessionsorotherwise.

The Company has a tailored and robust onboarding program for new directors, aimed to familiarize the new directors with key topics, such as the board's structure, governance and responsibilities, the Company's organizational structure, the Company's strategic objectives and key performance indicators (KPIs), the Company's business environment and market overview, financial reporting and legal proceedings. The program is formalized and tailored to take into account the unique backgrounds, experiences and expected committee responsibilities of each new director. The program includes an educational overview of theCompany's public disclosures, including website, regulatory filings, governance documents, investor presentations, and annual and long-term budget materials. In addition, we schedule meetings for the new directors with other directors, key executives and business leaders to gain business insights about the Company, and the culture of the board and how it operates. Additionalonboarding activities (such as site visits) are calendared throughoutthe yearto foster an ongoing onboarding program. The board operates according to annual and long-term plans, which include, among other things, trainings on various issues (such as climate change, sustainability, governance, compliance,HR, people trends, etc.), in addition to educational sessions on thebusinessenvironment,ourproducts,competitionview,compliance,andothertopics.
Our Board of Directors has established the following committees, which operate in accordance with written charters or procedures that set forth, among other things, such committee's structure, manner of operations, qualification andmembershiprequirements,responsibilitiesandauthorities.
| COMMITTEE NAME | MAIN RESPONSIBILITIES | COMMITTEE MEMBERS |
|---|---|---|
| AUDIT & ACCOUNTING(1) Statutory committee |
> Identifying and addressing flaws in the business management of the Company > Review and approve interested party transactions; determine criteria forclassificationandapprovalofinterestedparty transactions > Establishing whistleblower procedures > Overseeing the Company's internal audit system and the performance of its internalauditor > Appointment, compensation, oversight and scope of work assessment of theCompany'sindependentaccountingfirm > Monitoring ICL's financial statements and the effectiveness of its internal controls > Ensure the Company's compliance with legal and regulatory requirements andadherencetocorporategovernancebestpractices > Overseeing ICL's risk management, including monitoring the activities to manageandmitigate theidentifiedrisks |
Dafna Gruber (Chair) Dr.MiriamHaran Lior Reitblatt GadiLesin |
| HUMAN RESOURCES &COMPENSATION(2) Statutory committee |
> Recommending to the Board of Directors a policy governing the compensation ofofficersanddirectorsbasedonspecificcriteria > Recommending to the Board of Directors, from time to time, updates to suchcompensationpolicy > Reviewing the implementation of such compensation policy > Deciding whether to approve transactions with respect to terms of office and employment of officers and directors (which require approval by the compensationcommitteeundertheIsraeliCompaniesLaw) > Approving, under certain circumstances, an exemption from shareholder approvalof the terms of a candidate for chief executive officer (who meets certain non- affiliation criteria, in accordance with the provisions ofthe Israeli Companies Law) > Overseeing the Company's bonus and equity plans > Overseeing evaluation of top management and employees > Overseeing succession planning |
Dr.MiriamHaran (Chair) Dafna Gruber LiorReitblatt |
| CLIMATE, SUSTAINABILITY & COMMUNITY RELATIONS (3) Notstatutory committee, advisory only |
> Overseeing ICL's climate, sustainability, safety, environment and water management related risks an opportunities, targets, policies and programs > Overseeing ICL's community outreach programs, public relations and advocacy > Overseeing diversity and inclusion aspects in the Company |
Dr. Miriam Haran (Chair, Environmental Expert) Reem Aminoach SagiKabla Gadi Lesin |
| FINANCING COMMITTEE(4) Not statutory committee, advisory only |
> Overseeing ICL's financing and equity management and operations, including loans, equityofferings,hedging,debtandotherfinancingvehicles |
Sagi Kabla (Chair) AviadKaufman Avisar Paz DafnaGruber |

Under the Israeli Companies Law, the Audit Committee must consist of at least three directors who meet certain independence criteria and mustincludeallofthe Company's externaldirectors. The ChairoftheAudit Committee is requiredtobeanexternaldirector. In addition to meeting the requirements of Israeli law, our Audit and Accounting Committee also complies with the requirements applicableto U.S. companies that are listed on the NYSE and with SEC rules. All members of our Audit and Accounting Committee are also independent directors as such term is defined in SEC rules and the NYSE listing requirements. Our Board of Directors has determined that all ofthe membersof theAuditandAccountingCommitteearefinanciallyliterateasprovidedintheNYSErules.
Under the Israeli Companies Law, the Compensation Committee must consist of at least three directors who meet certain independence criteria and include all of the Company's external directors, who are required to constitute a majority of its members. The Chairman of the Compensation Committee must be an external director. The members of the Compensation Committee are remunerated for their service in accordancewiththeCompensationRegulationsgoverningthecompensationofexternaldirectors.
All members of our HR and Compensation Committee are also independent directors as such term is defined in the NYSE listing requirementsand SECrules.
Our Climate, Sustainability and Community Relations Committee is not a statutory committee and is not authorized to exercise any power of ourBoardofDirectorsandhasadvisoryauthorityonly.
Our Financing Committee is not a statutory committee and is not authorized to exercise any power of our Board of Directors and has advisory authorityonly.
| BOARD MEMBER | BOARD MEETING | AUDIT & ACCOUNTING COMMITTEE |
HR & COMPENSATION COMMITTEE |
CLIMATE, SUSTAINABILITY AND COMMUNITY RELATIONSCOMMITTEE |
FINANCING COMMITTEE |
|---|---|---|---|---|---|
| YoavDoppelt | 18/18 | ||||
| AviadKaufman | 18/18 | 4/4 | |||
| AvisarPaz | 18/18 | 4/4 | |||
| Dafna Gruber | 16/18 | 10/10 | 6/6 | 3/4 | |
| Gadi Lesin | 17/18 | 10/10 | 4/5 | ||
| LiorReitblatt | 18/18 | 10/10 | 6/6 | ||
| Michal Silverberg | 18/18 | ||||
| MiriamHaran | 18/18 | 10/10 | 6/6 | 5/5 | |
| Ovadia Eli (1) | 3/4 | 2/2 | |||
| Reem Aminoach | 16/18 | 5/5 | |||
| Sagi Kabla | 18/18 | 5/5 | 4/4 | ||
| Tzipi Ozer Armon | 17/18 |
1.Mr.EliretiredonMay10,2023,followingthe2023AnnualGeneralMeetingofshareholders.
By Order of the Board of Directors, Aya Landman, Adv. VP, Chief Compliance Officer & Corporate Secretary May 31, 2024
``
41
42
| Calculation ofAdjusted EBITDA(US\$M) | FY'23 | FY'22 | |
|---|---|---|---|
| Netincome | \$687 | \$2,219 | |
| AviadFinancing expenses, net | \$168 | \$113 | |
| Taxesonincome | \$287 | \$1,185 | |
| Less: Share in earnings of equity-accounted investees | (\$1) | (\$1) | |
| Operating income | \$1,141 | \$3,516 | |
| Depreciationand amortization | \$536 | \$498 | |
| Adjustments(1) | \$77 | (\$7) | |
| Adjusted EBITDA | \$1,754 | \$4,007 | |
| Calculation of Free Cash Flow (US\$M) | FY'23 | FY'22 | |
| Cash flow from operations | \$1,595 | \$2,025 | |
| Additions to PP&E, intangible assets, and dividendsfromequity-accountedinvestees (2) |
(\$777) | (\$710) | |
| \$818 | \$1,315 |
(1) Divestment related items and transaction costs from acquisitions, legal proceedings, dispute and other settlement expenses aswellas impairmentanddisposalofassets,provisionfor closureandrestorationcosts.
(2) Also includes proceeds from sale of property, plants and equipment(PP&E).
| Calculation of adjusted net income attributable (US\$M) | FY'23 | FY'22 |
|---|---|---|
| Netincome, attributable | \$647 | \$2,159 |
| Adjustments(1) | \$77 | (\$7) |
| Totaltaxadjustments | (\$9) | \$198 |
| Adjustednetincome,attributable | \$715 | \$2,350 |
| Calculation of Adjusted Diluted Earnings Per Share (US\$M,excludingper sharedata) |
FY'23 | FY'22 |
| Adjusted net income, attributable | \$715 | \$2,350 |
| Weighted-average number of diluted ordinary shares outstanding(inmillions) |
1,291 | 1,290 |
Note: Numbers may not add, due to rounding and set-offs.
(1) Divestment related items and transaction costs from acquisitions, legal proceedings, dispute and other settlement expenses aswellas impairmentanddisposalofassets,provision for closureandrestorationcosts.
(2) Adjusted diluted EPS is calculated by dividing adjusted net income attributable by weightedaverage number of diluted ordinarysharesoutstanding.
``
| Words | Meaning |
|---|---|
| "Person" | Including a company, cooperative association or any other group of Persons, whether associated or not associated. |
| "Director" | A member of the Board of Directors of the Company, including a substitute Director. |
| "the Board of Directors" | The Board of Directors of the Company serving at that time. |
| "the Company" | ICL Group Ltd. |
| "the Seal" | The Company Seal. |
| "the Stamp" | The Company Stamp. |
| "the Office" | The registered Office of the Company, as will be from time to time. |
| "the Special State Share" |
As defined in these Articles of Association. |
| "the Law" or "the Companies Law" |
The Companies Law, 5759-1999, including all the changes inserted therein from time to time, or any law which supersedes or replaces it. |
| "the Shareholders Register" |
The register of shareholders to be maintained in accordance with Section 127 of the Law, and/or, if the Company elected to maintain an additional Shareholders Register as provided in Section 138 of the Law, any such additional Shareholders Register. |
| "the Material Shareholders Register" |
The register of material shareholders to be maintained in accordance with Section 128 of the Law. |
| "Writing" | Print, lithograph, photograph and any other way of fixing or imprinting words in visible form or, subject to the provisions of the law permitting it – electronically. |
| "Officer" | As this term is defined in the Companies Law, as amended from time to time. |
| "Securities" | Including a share, debenture, or a right to purchase, convert or sell any of them, whether registered or bearer. |
| "Securities Law" | Securities Law, 5729-1968. |
"Administrative proceeding" A proceeding pursuant to Chapters H3 (Imposition of a financial sanction by the Securities Authority), H4 (Imposition of administrative means of enforcement by the Administrative Enforcement Committee) or I1 (Arrangement for refraining from proceedings or termination of proceedings, contingent upon conditions), of the Securities Law, as may be amended from time to time.
"these Articles" or "these Articles of Association"
These Articles of Association, as worded here or as changed from time to time.
Subject to the provisions of this Article, each term, word and expression in these Articles shall have the meaning given then in the Law, unless the written text necessitates another meaning.
Anything stated in the singular shall mean also the plural and vice versa, and anything stated in the masculine shall mean also the feminine, and vice versa.
The headings appearing in these Articles of Association are intended for convenience only, and shall not be used for the interpretation of these Articles of Association.
A change, amendment or cancellation of this Article 4 shall be deemed to be a change of the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 4, shall be void and invalid without receipt of the consent of the holder of the Special State Share. Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
In this Article 8(b)(1) – Transfer of material assets not in the ordinary course of the Company's business, means – including simultaneously or in parts, whether in one transaction or in a series of transactions of each of these:
(a) Transfer of shares or other Securities in the Company, including Securities held by the Company in another corporation, as a result of which another will hold more than 25% of the voting rights in the Company or the other corporation, or as a result of which the control in the Company or in the other corporation will transfer or is likely to transfer to another holder (in this paragraph, Transfer – including allotment of Securities).
stated in this Article 8(b)(3) concerning holding or acquisition of shares shall apply also to their lien or pledge.
The Company shall make such voting contingent also in relation to whoever wishes to vote at a General Meeting or to appoint Directors by virtue of the shares constituting 14% or more of the issued share capital of the Company.
companies, the center and management of whose business is in Israel.
A change, amendment or cancellation of this Article 8(b) shall be deemed to be a change of the rights attaching to the Special State Share, and shall not be made without the consent of the holder of the Special State Share. Any decision or action, which is contrary to or not in compliance with the provisions of this Article 8(b), shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any change of these Articles of Association in a way liable to prejudice, directly or indirectly, the rights attaching to the Special State Share, shall be deemed to be a change of the rights attaching to the Special State Share. Any decision or action which is liable to prejudice, directly or indirectly, the rights attaching to the Special State Share, shall not be done without the consent of the holder of the Special State Share, and shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Taking into consideration the provisions of the Law and the provisions on this matter in these Articles of Association, where they exist, the Company can create shares with privileges or with deferred rights or with rights of redemption or with other special restricted rights or restrictions in connection with the distribution of the dividends, a right of opinion, clearance of fund capital, or in connection with other matters, as may be determined by the Company from time to time, and to issue them from time to time, in accordance with a resolution of the Board of Directors.
Where two or more Persons are registered as joint holders of a share, each of them may give binding receipts for any dividend or other moneys in connection with that share.
premium, shall be considered, with regard to these Articles of Association, as a call duly made by the Board of Directors and for which notice was duly given, and the date of payment is the date fixed for payment. In case of non-payment, all the Articles of these Articles of Association, which deal with payment of interest and expenses, forfeiture of shares, and all the other Articles relating to calls, shall apply.
those amounts at the maximum rate permitted at that time by law, from the date of the forfeiture to the date of the payment. The shareholder shall be required to fulfill all the claims and demands which the Company could have made in relation to the shares up to the date of the forfeiture, without deduction or discount for the value of the shares on the date of forfeiture. His obligation will be discharged after the Company receives the full consideration, which the shareholder undertook to pay, plus the expenses involved in the sale. If the consideration received from the sale of the forfeited shares exceeds the consideration which the debtor undertook to pay, the debtor shall be entitled to recoup the partial consideration he gave for them, if any, provided that the consideration remaining in the hands of the Company shall be not less than the full consideration which the debtor undertook to pay plus the expenses involved in the sale.
The Board of Directors may, but is not obligated to, require the shareholder to pay some or all of these sums of money, if it sees fit to do so. Forfeiture of a share shall bring with it, a the time of forfeiture, cancellation of any right in the Company and any claim or demand against it in relation to the share, except for those rights and obligations which are excluded from this rule by virtue of these Articles of Association or which the law vests in or imposes upon a former shareholder.
The above lien shall apply to all the dividends announced from time to time on those shares.
proceeds of the sale, and after those shares are registered in his name, no Person shall appeal the validity of the sale.
such terms as it sees fit. Any decision or action made by the Board of Directors as aforesaid in this Article shall be final and absolute, and any transfer or sale of shares carried out in accordance with this Article shall be acceptable towards any third party.
Without derogating from the aforesaid, no allegation shall be entertained concerning the rights of the transferee concerning a share sale proceeding, and the transferee may demand that the Company's books be altered accordingly.
The provisions of these Articles of Association concerning forfeiture and lien of shares shall apply, mutatis mutandis, to a sale of shares pursuant to this Article insofar as they do not contradict the aforesaid.
A change, amendment or cancellation of this Article 38(a) shall be deemed to be a change of the rights attaching to the Special State Share, and shall not be made without the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 38(a), shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent or waiver or approval of the holder of the Special State Share shall be given in Writing.
(b) Subject to the aforesaid, fully paid up shares can be transferred without need for the approval of the Board of Directors.
The aforesaid notwithstanding, the Special State Share cannot be transferred.
| I, ___, of ___, in consideration of NIS ___ | |
|---|---|
| which was paid to me by ____ of _______ | |
| (hereinafter called "the Transferee"), hereby transfer to the Transferee ______ shares | |
| of NIS __ each, which are marked with the numbers __ to ____ | |
| inclusive, of ICL Group Ltd., to be held by the Transferee, the managers of his estate, | |
| his guardians and legal representatives, in accordance with the terms under which I |
held them prior to signing this deed, and I, the Transferee, hereby agree to accept the above shares on those terms.
In witness whereof we have affixed our signatures this ____ day of the month of __________, in the year _______.
The Transferor The Transferee Witness to the Transferor's signature Witness to the Transferee's signature
Directors, including a subject requested in advance of the Board of Directors by one or more shareholders who have at least one percent of the voting rights in the General Meeting, provided that the subject is appropriate for discussion in the General Meeting.
Meeting, the shareholders who are present at the Meeting shall elect one of themselves to chair the Meeting.
invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
If a General Meeting is adjourned without changing its agenda, to a date which does not exceed 21 days, notices and invitations relating to the new date will be given as early as possible, and no later than seventy-two hours before the General Meeting.
proven by the minutes or by another document, all in accordance with the foundation documents of the empowering company.
| I, ____ of __, as owner of _ _____ shares | |||||||
|---|---|---|---|---|---|---|---|
| in | ICL | Group | Ltd., | hereby | appoint | Mr./Mrs./Ms_____ | of |
| ___, or in his/her absence, Mr./Mrs./Ms __ of | |||||||
| ______, to vote for me at the (Annual / Special) General Meeting of the | |||||||
| Company | adjourned Meeting of that Meeting. | which will be held on the _ of __, ____ – and at any |
In witness whereof I have affixed my signature on the ____ day of __________, _____.
A change, amendment to cancellation of thus Article 82(d) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 82(d), shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
A change, amendment to cancellation of thus Article 83 shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action which contravenes or does not comply with the provisions of this Article 83, shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
A change, amendment to cancellation of thus Article 84 shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 84, shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
Company that are controlled by the Company, shall not be considered as having a personal interest in a transaction between the said subsidiaries, due to his being an officer in the transacting parties.
"extraordinary transaction" means – a transaction which is not in the normal course of the Company's business, or a transaction which is not on market terms, or a transaction liable to have a material effect on the profitability, assets or liabilities of the Company.
A change, amendment to cancellation of thus Article 92(c) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 92(c), shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
If a meeting of the Board of Directors is not convened within 14 days of the date of the demand or from the date of the notice or report of the CEO or from the date of the notice of the auditor, each of those listed above may convene a meeting of the Board of Directors, which shall discuss the subject described in the demand, notice or report, as the case may be.
(a) An invitation to a meeting of the Board of Directors shall be made in writing, by telephone, by facsimile or by email and shall be delivered to the Directors at least 48 hours prior to the date set for the meeting, unless the Chairman of the Board, and in his absence the Vice-Chairman of the Board, determines that an urgent meeting of the Board of Directors must be held, in which case the invitation to the Board of Directors can be at shorter notice before the meeting, as the Chairman of the Board or the Vice-Chairman decides, as the case may be. The invitation to a meeting of the Board of Directors shall state the date and time of the meeting, the place where it will convene, and give reasonable detail of the subjects on the agenda.
(b) A Director who is an Israeli resident, who is out of the country at any time, shall not be entitled, during his absence, to receive an invitation to a meeting of the Board of Directors, but his substitute shall be notified if, subject to the provisions of Article 97 of these Articles of Association, the Director is entitled to appoint a substitute.
Unless determined otherwise in these Articles of Association, a substitute Director shall be considered as a Director in all matters and respects, except in the matter of appointing a substitute Director and he shall bear responsibility for his actions as a substitute Director. The appointment of a substitute Director shall not negate the responsibility of the Director for whom he substitutes, and it shall apply with attention to the circumstances of the matter, including the circumstances of the appointment of the substitute Director and the duration of his tenure.
The aforesaid notwithstanding, approval of the General Meeting for an action carried out by the Board of Directors, if at the time it was carried out a majority of the members of the Board of Directors were not citizens and residents of Israel, shall be subject also to the approval of the holder of the Special State Share.
the subjects listed in Section 112(a) of the Law, on which it may delegate of its power to Board of Directors committees for a recommendation only, or to the Genera Manager as it sees fit and subject to the provisions of the Law. A Person who is not a member of the Board of Directors can serve also on a committee of the Board of Directors whose function is to advise the Board of Directors or to make recommendations only.
Without derogating from the generality of the aforesaid, and subject to any law, the quorum required for conducting the affairs of a Board of Directors committee shall be a majority of the members of the committee. The Board of Directors shall appoint a chairman for each Board of Directors committee. The Chairman of the Audit Committee shall be one of the Company's external directors. Every resolution shall be adopted by a majority vote, and in the event of a tied vote, the chairman of the committee shall not have an additional or casting vote.
it, all where the matter concerns legal proceedings which are material to the Company.
Any power of attorney as aforesaid can contain the same powers for the defense or convenience of Persons who come into contact with such legal representatives, as the Board of Directors deems appropriate.
(c) The CEO shall deliver, once every three months, to the holder of the Special State Share, a report on all the transaction in assets which were approved by the Board of Directors in the three months preceding the date of the report, on changes in the holdings in the share capital and on voting agreements which he knows to have been signed, if signed, in that period among the shareholders of the Company.
A change, amendment to cancellation of thus Article 117(c) shall be deemed to be a change in the rights attaching to the Special State Share, and shall not be made except with the consent of the holder of the Special State Share. Any decision or action, which contravenes or does not comply with the provisions of this Article 117(c), shall be void and invalid without receipt of the consent of the holder of the Special State Share.
Any consent, waiver or approval of the holder of the Special State Share shall be given in Writing.
Every such minutes from a Board of Directors meeting or from a meeting of a Board of Directors committee or from a General Meeting of the Company, if seen to be signed by the Director who conducted the meeting or by the chairman of that meeting, shall be accepted as prima facie evidence of the matters recorded therein.
(b) The books of minutes of the General Meeting shall be kept in the head Office, and shall be open for scrutiny by the shareholders, free of charge.
The aforesaid notwithstanding, Notices to the holder of the Special State Share shall be in Writing, sent by registered mail, and in accordance with the provisions of these Articles of Association.
The aforesaid notwithstanding, a Notice to the holders of the Special State Share shall be sent by registered mail.
The Company may deliver any Notice to the shareholders, including a Notice concerning the convening of a General Meeting, by publishing the Notice in two daily Israeli Hebrew-language newspapers of wide circulation, and the date of publication in the newspaper shall be considered the date on which the Notice was received by the shareholders.
Company's actual activity, and the sum or criteria specified by the Board of Directors are reasonable under the circumstances; (2) in respect of the events specified in sub-sections (b)-(ef) above (inclusive): or by way of indemnification ex post facto, and all as stipulated in Section 260(b) of the Companies Law and Section 56H(b) of the Securities Law, as may be amended from time to time.
* * * * * *

To: Ms./Mr.________
_______ 2024
Without detracting from the generality of the aforementioned statement, the insurance coverage will apply to all liability imposed upon you as a result of an action you took by virtue of your being officeholder in the Company, in any of the following:


indictment in which you were convicted for an offense that does not require proving criminal intent.

competition, including restrictive trading agreements, monopolies, split-offs or mergers.

"maximum indemnification amount"). The maximum indemnification amount or any part thereof will be paid to the officeholders according to the date on which the liability for which such indemnity is requested, was created.
The Company will be entitled to take upon itself the handling of the aforementioned proceedings and/or refer their handling to an attorney that the Company selects for this purpose, unless that attorney is unacceptable to you for reasonable reasons or because of

circumstances that, in your opinion or the opinion of the attorney, create a conflict of interest between your defense and the defense of the Company.
The Company and/or the aforementioned attorney may act independently when handling the aforementioned proceedings (but providing you with regular reports and consulting with you and your legal counsel) and bring the proceedings to a conclusion as it sees fit.
At the request of the Company, you shall sign on any document authorizing the Company and/or the aforementioned attorney to handle your defense on your behalf in the aforementioned proceedings and represent you in all related matters, in accordance with the above.
In order to remove any doubt, it is clarified that the Company and/or aforementioned attorney may not, in the context of criminal proceedings, plead guilty to any charges in your name or agree to any plea bargain without your consent. Furthermore, the Company and/or the attorney may not, in the context of civil proceedings, admit in your name (whether in court or negotiations for compromise) to the existence of any events to which you are not entitled to indemnity under the provisions of this notice of indemnification and/or by law, without your consent. Despite this, there is nothing in the above to prevent the Company and/or the aforementioned attorney, with the consent of the Company, to reach a financial arrangement with the claimant in a civil proceeding without your agreement, on the condition that this does not in any way admit to the existence of any event for which you are not entitled to indemnity under the provisions of this notice of indemnification and/or by law.
13.5. In this Notice of Indemnification –
"Officeholder" – in accordance with its meaning in the Companies Law, including the legal counsel, company secretary, comptroller or internal auditor.
"Administrative proceeding" – proceedings pursuant to Chapter 8.3 (Imposition of Monetary Sanctions by the Authority), Chapter 8.4 (Imposition of Administrative Enforcements Means by the Administrative Enforcement Committee) or Chapter 9.1

(Arrangements for the Prevention or Cessation of Conditional Proceedings) of the Securities Law, as amended from time to time.
"Another person" – including the case of a suit filed against an officeholder as a derivative suit.
If the full amount of fees requested is not approved, you shall have the right to receive from the Company the sum total of the reasonable, approved fees, and pay the balance from your own account.
In order to remove any doubt, it is hereby clarified that this section is subject to the provisions of the Officeholders Liability Insurance policy regarding the identity of the representing attorney, and the provisions of this section shall not apply if the appointment of the other attorney will allow the insurance company to be released from its liability under the policy or diminish that liability.

with the addition of C-o-L linkage and interest for the period during which you were entitled to refund of the sum from the prosecution.
The Company will inform you of the details of any compromise agreement. In the event that a disagreement arises between you and the Company about whether or not the compromise complies with the provisions of this section, agreement will be bought for quick decision by an arbitrator who shall be appointed at the request of the Company or at your request. The arbitrator will be appointed with agreement of the parties within seven days after one of the parties requests that the disagreement be referred to the decision of an arbitrator, and if agreement is not reached between the parties as stated, the identity of the arbitrator (who shall be a retired district court judge or a retired Supreme Court judge) will be determined by the chairman of the Israel Bar Association. The Company will pay the costs of arbitration, including the attorneys' fees.
The Company and/or Company's attorney shall not agree to a compromise for an amount that exceeds the amount of indemnity to which you are entitled, unless you have given prior written consent and, if the consent of the insurance company is also required, then it also must give prior consent.

If the Company has made any payments to you, as the result of one of the aforementioned cases, the provisions of section 15, above, shall apply.
Sincerely yours,
_______________________
ICL Group Ltd.
I agree to the above,

Name Signature Date
__________________ ___________________ __________________
ICL Millennium Tower, Aranha St. 23 P.O.B 20245 Tel Aviv 6120201 Tel. 972 3 6844400 Fax. 972 3 6844444 www.icl-group.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.